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FEASIBILITY OF USING VIRTUAL UNENHANCED IMAGES TO REPLACE PRE-
CONTRAST IMAGES IN MULTIPHASE RENAL CT EXAMINATIONS 
 
Dawn Olivia Popnoe, B.S. 
Advisory Professor: Kyle Jones, Ph.D. 
 
Multiphase renal CT exams are a commonly used imaging technique for the diagnosis of 
renal masses. The pre-contrast, or true unenhanced (TUE), image provides a baseline for 
enhancement measurements which is an important criteria used to characterize renal lesions, 
consequently it is crucial that CT numbers measured in TUE images be accurate. The purpose of 
this work is to assess the feasibility of replacing TUE with virtual unenhanced (VUE) images 
derived from DECT data in renal CT exams. Eliminating TUE image acquisition would reduce 
patient dose and increase patient throughput, improving clinical efficiency.   
A retrospective study was conducted for 60 consecutively selected patient exams. VUE 
and TUE images were compared qualitatively and the differences were tested using a Bayesian 
Hierarchical model. VUE images were found to be inferior to TUE images for visualization of 
major vessels and depiction of liver parenchyma. CT numbers were measured in the liver, spleen, 
spine, aorta, cystic lesions, subcutaneous fat, renal cortex and medulla, and the differences were 
tested with a Student’s paired t-test. There were significant differences between TUE and VUE 
measurements ( p-value > 0.05) in the spleen, spine, aorta, renal cortex, subcutaneous fat, and 
inferior vena cava. However, evaluation of the clinical relevance based on grayscale perceptibly 
indicated that the difference for the spleen and subcutaneous fat are not clinically meaningful.    
The rapid kVp-switching GE CT750HD scanner was used to assess enhancement 
accuracy when using VUE compare to TUE images as the baseline for enhancement calculations 
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across a wide range of clinical scenarios simulated in a phantom study, and the results were 
analyzed using Bayesian Hierarchical models. For simulation of angiomyolipoma and benign 
cystic lesions, enhancement values were not significantly different. However, for simulation of 
Bosniak category II-IV lesions, differences in measured enhancement were found to be 
significant. Additionally, the effect of ASIR level used in image reconstruction was assessed, and 
found not to affect measured CT number using a mixed effects model.  
Differences in measured enhancement values for simulated borderline enhancing renal 
lesions demonstrate that replacement of TUE with VUE images is not feasible with the current 
iteration of the algorithm.  
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Chapter 1.  Introduction and Background 
1.1 Computed Tomography 
 Computed Tomography (CT) is a commonly used imaging technique in volumetric 
dataset of the patient anatomy is acquired and reconstructed to provide a three-dimensional 
representation of the linear attenuation coefficients contained within each voxel in the field of 
view (FOV). This imaging modality provides a non-invasive method for patient diagnosis, and is 
performed annually around 70 – 80 million times in the United States [1]. First introduced in 
clinical practice in 1972, CT has since revolutionized both medical imaging and the practice of 
medicine [2].      
1.1.1 Single Energy Computed Tomography 
Single Energy Computed Tomography (SECT), commonly referred to as conventional 
CT, is based on the fact that each material within the CT field of view (FOV) has a characteristic 
linear attenuation curve, which in turn dictates the ways in which each material interacts with an 
X-ray beam. CT images are reconstructed from line integral measurements of X-ray attenuation 
through the human body using mathematical concepts first discussed by Johann Radon in 1917 
[2].  
The primary modes for X-ray interaction in the energy range used for diagnostic CT 
imaging are the photoelectric effect and incoherent (Compton) scattering. The photoelectric effect 
occurs when an incident X-ray photon transfers all of its energy to an inner shell atomic electron, 
which is then ejected from the atom. The probability of this interaction is approximately 
proportional to the atomic number cubed and inversely proportional the energy cubed [1]. This 
energy dependence, in conjunction with differences in K absorption edges of different atomic 
elements, is a fundamental concept facilitating the dual energy technique [3]. Incoherent 
scattering refers to the interaction of an incident photon with a valence electron, where the 
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electron is ejected from the atom, and the photon is scattered with a fraction of its initial energy. 
This is the predominant interaction mechanism in the diagnostic energy range above 26 keV [1]. 
In contrast to the photoelectric effect, Compton scatter is almost independent of photon energy, 
and instead is strongly dependent on the electron density of a material. 
An X-ray source that is contained within the CT scanner produces a spectrum of X-rays 
with a peak kilovoltage (kVp) typically ranging between 80 – 140, and a corresponding array of 
detectors is aligned opposite of the X-ray source [1]. During data acquisition, the X-ray source 
and detector array rotate synchronously around the axis of the gantry. Originally, CT images were 
acquired with axial scanning, which involves the translation of the object to be imaged along the 
z-axis of the scanner between sequential cycles of the gantry, resulting in the reconstruction of 
one or more images per rotation, depending on the number of detector rows. Helical CT defines a 
mode of operation in which the object to be imaged is translated along the z-axis while the X-ray 
source is rotating, resulting in the volumetric set of line integrals of attenuation through the 
object. Interpolation is then used to produce sets of coplanar projections from the three-
dimensional data set which are then reconstructed into image sets using filtered back projection or 
iterative reconstruction [4]. In either case, the images produced are attenuation maps of the 
materials and tissues contained within the field of view (FOV), each having a characteristic linear 
attenuation coefficient, 𝜇, which is dependent on photon energy and therefore kV and beam 
filtration [5]. The image is comprised of an array of voxels, each with a gray scale value based on 
the X-ray attenuation within that voxel. The gray scale value is referred to as a Hounsfield Unit 
(HU) and is defined as [1]: 
𝐻𝑈(𝑥, 𝑦, 𝑧) = 1000 ∗ (
𝜇(𝑥,𝑦,𝑧)−𝜇𝑤
𝜇𝑤
)      Equation 1.1.1-1 
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where 𝜇(x,y,z) is the average linear attenuation coefficient measured in a voxel located at (x,y,z) 
within the patient and 𝜇w is the linear attenuation coefficient of water. This provides a relative 
attenuation measurement in which the attenuation is scaled to that of water (HU=0).  
1.1.2 Dual Energy Computed Tomography 
Dual Energy Computed Tomography (DECT) is an extension of SECT in which two data 
sets are acquired using different X-ray energy spectra. DECT was originally proposed in the late 
1970s, but technical limitations of early CT scanners limited the success of the technique [1, 6-9]. 
DECT was abandoned because the acquisition times of early scanners were long and two 
consecutive scans were needed which led to motion misregistration between data sets, as well as 
additional radiation exposure [9]. With the advanced capabilities of newer scanners, there has 
been renewed interest in the clinical use of DECT. One potential benefit of this technique is that it 
can provide information regarding the material composition within each voxel by exploiting 
attenuation variations of photon absorption at different energies as well as attenuation differences 
of materials with high atomic numbers [9]. In addition to enhancing material differentiation, 
DECT has the potential to reduce beam hardening artifacts [8].  
DECT has the potential to expand the capabilities of CT by allowing for the estimation of 
the linear attenuation curve for each voxel in the object, providing both spatial and material 
information, as opposed to only a spatial map of scalar HU values [10]. This is accomplished by 
measuring the attenuation of materials in the FOV using two different effective X-ray energies 
and then extrapolating, using knowledge of the exponential behavior of X-ray attenuation of 
materials, to estimate the full attenuation curve. This curve can then be compared to known 
attenuation curves to gain information as to composition of the material.  
The foundation of this material decomposition technique exploits the fact that the 
attenuation coefficient for a given material is a function of a unique combination of photoelectric 
and incoherent scattering probabilities, which are related to effective atomic number and electron 
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density, respectively. For a given material, the attenuation coefficient as a function of energy µ(E) 
may then be represented as a unique combination of photoelectric and incoherent scatter 
coefficients:  
𝜇(𝐸) = 𝛼𝑓𝑃𝐸 + 𝛽𝑓𝐶         Equation 1.1.2-1 
where fPE represents the photoelectric dependence, which depends strongly on atomic number and 
therefore provides information as to the composition of the object, and fC represents the Compton 
scatter coefficient, which depends strongly on electron density and is therefore proportional to 
mass density [11]. The weighted linear combination of these two coefficients can  represent the 
mass attenuation coefficient of any material in the diagnostic energy range [12]. However, 
discontinuities at the K-edge of a material can complicate the simplified assumption that this is a 
linear combination. Consider as an example iodine, which is commonly used as a contrast agent 
in diagnostic imaging due to its 33.2 keV K-edge. If the effective energy of the beam is just above 
this K-edge, the probability of photoelectric interaction (fPE) will be approximately six times 
greater than the probability for energies just below the K-edge, 33.1 keV [1].  
 Following on this technique, a basis pair of two materials may be chosen, such that all 
materials contained within a given voxel in a DECT image are assumed to be a weighted 
combination of the selected basis pair, e.g., water and iodine. Note that it is crucial that the 
selected materials differ substantially in atomic number and electron density so that they 
consequently differ in photoelectric and incoherent scatter attenuation cross sections, resulting in 
a large separation between the linear attenuation curves. The total linear attenuation coefficient in 
any voxel can be expressed as a weighted combination of the attenuation of basis materials 1 and 
2: 
 𝜇(𝐸) = 𝛿1 ∗ 𝜇1(𝐸) + 𝛿2 ∗ 𝜇2(𝐸)    Equation 1.1.2-2 
where 
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𝜇1(𝐸) = 𝛼1𝑓𝑃𝐸 + 𝛽1𝑓𝐶    𝑎𝑛𝑑    𝜇2(𝐸) = 𝛼2𝑓𝑃𝐸 + 𝛽2𝑓𝐶     Equation 1.1.2-3 
In Equation 1.1.2-2 the variable δi represents the weighting of the corresponding basis material 
such that the combination of weighted attenuation from each material in the basis pair yields the 
measured attenuation of the material in the voxel. The system of equations given in Equation 
1.1.2-3 can be solved for fPE and fC: 
𝑓𝑃𝐸 =
𝜇2𝛽1−𝜇1𝛽2
𝛼2𝛽1−𝛼1𝛽2
    Equation 1.1.2-4 
𝑓𝐶 =
𝜇2𝛼1−𝜇1𝛼2
𝛼1𝛽2−𝛼2𝛽1
    Equation 1.1.2-5 
Substituting Equations 1.1.2-4 and 1.1.2-5 into Equation 1.1.2-3 followed by 1.1.2-2 and then 
rearranging yields:  
𝜇(𝐸) = 𝛿1 [𝛼1 (
𝜇2𝛽1−𝜇1𝛽2
𝛼2𝛽1−𝛼1𝛽2
) + 𝛽1 (
𝜇2𝛼1−𝜇1𝛼2
𝛼1𝛽2−𝛼2𝛽1
)] + 𝛿2 [𝛼2 (
𝜇2𝛽1−𝜇1𝛽2
𝛼2𝛽1−𝛼1𝛽2
) + 𝛽2 (
𝜇2𝛼1−𝜇1𝛼2
𝛼1𝛽2−𝛼2𝛽1
)]  
Equation 1.1.2-6 
Equation 1.1.2-6 represents the attenuation coefficient for any material as a weighted combination 
of the selected basis pair. All subscripts 1 correspond to attenuation properties of the first basis 
material, and subscripts 2 correspond to the second basis material. Attenuation data can then be 
measured at two different effective X-ray energies, resulting in two equations (equation 1.1.2-6 at 
the high and low energy), µL and µH, with two unknowns, δ1 and δ2. Each unknown variable, δi, 
represents the fraction of the material within the voxel attributed to each of the basis materials. 
Line integrals can then be taken over the linear attenuation coefficient for each ray of each 
projection and corresponding detector element and used to make measurements of the function 
being reconstructed to generate an image [11]. The resulting intensity equations can then be 
solved for δ1 and δ2, which are the weightings that combine to yield the unique attenuation of the 
material in the voxel. An example of material decomposition with a basis pair of water and iodine 
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for a voxel containing bone is shown in Figure 1. The light blue line indicates the estimated 
weighted combination of water and iodine attenuation coefficients, as described.  
 
Figure 1. Bone material attenuation coefficient represented as a weighted combination of 
water and iodine attenuation coefficients [13] 
 There are two commonly used techniques for DECT data acquisition. The first is a dual-
source technique that involves the use of two X-ray sources mounted nearly 900 apart, a concept 
that was first proposed only a few years after CT was first introduced into clinical practice and 
then re-introduced in 2006 [7]. A benefit of this technique is that the tube current (mA) can be 
selected independently for each X-ray source, which ensures similar X-ray fluence at both beam 
energies. This system also offers the potential for increased separation between the two energy 
spectra by filtering the high energy X-ray source which increases the contrast between two 
materials and therefore improves the performance of DECT algorithms [7]. Disadvantages of this 
technique include a limited DECT scan field of view (SFOV) resulting from the smaller coverage 
of the second detector array and cross scatter between non-corresponding orthogonal detector 
rows [7]. Additionally, the angular separation of the X-ray sources results in a temporal 
difference on the order of 100 milliseconds between the high and low energy projections, which 
can introduce artifacts from patient motion and result in mis-registration of the two data sets [7]. 
The second technique currently used for commercial DECT data acquisition involves a 
single X-ray source with fast kVp switching.  For this technique, the high voltage generator 
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alternates between high and low kVp at each projection angle, creating an interleaved set of high 
and low energy projections. The nearly simultaneous acquisition of the two data sets results in 
better temporal registration, which reduces the potential for motion artifacts while still using the 
entire SFOV for DECT [8]. Fast switching between two kVps does have technical challenges, 
including the rise and fall times of the high voltage waveforms, which complicates the 
determination of the effective energy for the high and low kVp projections [14]. Because this rise 
and fall of the waveforms occurs during data acquisition, it reduces the achievable separation 
between the energy spectra [7]. Another consequence of this technique, which uses a single 
detector array, is that the view integration time is limited by the primary decay of the detector and 
afterglow performance [8]. The Gemstone scintillator (General Electric Healthcare, Milwaukee, 
WI) has been developed to minimize this integration time limitation, as it has a decay time of 30 
ns which is 100 times faster than the more commonly used gadolinium oxysulfide (Gd2O2S) and 
afterglow levels that reach only 25% of gadolinium oxysulfide [8]. Energy separation is further 
limited by the use of a single source to produce both spectra, as it is not possible to filter the high 
energy spectrum as describe previously for the dual source technique.  
The GE HD750 (General Electric Medical Systems, Milwaukee, WI) is a commercially 
available DECT scanner that uses the rapid kVp switching technique. This system includes 
analysis software, the GSI [Gemstone Spectral Imaging] Volume Viewer (General Electric 
Healthcare, Milwaukee, WI), that allows for two material basis pair decomposition image sets to 
be reconstructed based on a user selected material basis pair. This system also includes MSI 
[Material Suppressed Iodine] analysis software that allows for the reconstruction of Virtual 
Unenhanced (VUE) images in which the iodine volume is replaced with an equivalent volume of 
blood to generate a virtual non-contrast data set from data acquired after the administration of 
iodine contrast. The focus of this study will be on assessing the functional capabilities of these 
VUE images generated from MSI software.    
 8 
 
1.2 Classification of renal lesions 
Abdominal multiphase CT exams are a commonly used non-invasive imaging technique 
for the  classification of renal lesions [15]. The CT exams are often used to distinguish hyper-
attenuating renal cysts from enhancing renal masses after a contrast agent is administered 
intravenously [3]. Multiphase renal CT exams include a non-contrast phase which is followed by 
the administration of a contrast agent, typically iodine based, and one or more post-contrast 
imaging phases. Iodine is commonly used as the contrast agent due to the high contrast it offers 
relative to the tissues in the human body. Enhancement can be quantified by comparing the 
measured CT number of a lesion in the non-contrast image to the measured CT number of the 
same lesion in the post-contrast image. Previously a difference of 10 HU between non-contrast 
and post-contrast images was the minimum criterion for enhancement [16]. However, with the 
advent of helical CT it has been suggested that this threshold of 10 HU should be increased to 
account for artifacts from helical interpolation, and enhancement is currently characterized 
definitively as a change in CT number of approximately 20 HU or greater between pre- and post-
contrast phases [17]. The exact change considered to be positive for enhancement has not been 
universally agreed upon for helical CT, and may also vary depending on acquisition parameters, 
including position within the FOV and the calibration of the CT scanner used [18]. 
1.2.1 Renal Cell Carcinoma 
Renal cell carcinoma (RCC) is the most common kidney cancer in adults, accounting for 
approximately 90% of renal neoplasms and 3% of all adult malignancies, and resulted in 
approximately 14,00 deaths in 2014 [19]. RCC is an aggressive disease that forms in the lining of 
the proximal tubular epithelium, and has a 5-year survival rate of 95% for stage 1 disease, but less 
than 20% for state 4 disease [20].  
 The diagnosis of RCC based on the appearance of the lesion on CT imaging can vary 
widely in difficulty. Diagnosis of a simple, non-enhancing cyst is straightforward while 
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classifying complex lesions is much more challenging [15]. In an effort to standardize the 
classification and management of renal lesions, the Bosniak Classification system was proposed 
in 1986 [16] and was updated in 2005 [16, 21]. A simplified description of the four classifications 
for renal lesions according to the Bosniak system is given in Table 1 [21]. 
Category Description 
I A benign simple cyst that uniformly measures water density and does not enhance  
II A benign cyst that may contain a few hairline thin septa in which “perceived” (not 
measureable) enhancement may be present. Cysts in this category do not require 
further evaluation. 
IIF A cyst that may contain multiple hairline thin septa and “perceived” enhancement 
may be present. Calcification may be present, but there is no measurable 
enhancement. Cysts in this category require further evaluation to prove benignity. 
III “Intermediate” cystic masses in which measurable enhancement is present. These 
are surgical lesions that may prove to be benign or malignant, such as RCC 
IV Clearly malignant cystic masses that meet criteria III and additionally contain 
enhancing soft-tissue adjacent to the wall or septum. These include cystic 
carcinomas and require surgical removal. 
Table 1. Bosniak renal cyst classification system [21] 
 
During a typical multiphase renal CT exam a patient undergoes an unenhanced scan, 
followed by intravenous administration of a contrast agent and several post-contrast scans, some 
of which may be delayed by several minutes to evaluate washout of the contrast. Studies have 
shown that if the patient has an enhancing renal mass, such as RCC, the mass will have a 
substantial non-calcified region with a CT number measuring within a range of 20-70 HU on 
unenhanced CT, while normal renal parenchyma will measure approximately 30 HU [22]. In a 
post-contrast scan acquired during the corticomedullary phase, studies have shown that RCC will 
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enhance significantly more than a benign cyst (112.9  HU vs 59.8 HU, respectively [23]) and that 
a difference of greater than 42 HU in the measured enhancement during the corticomedullary 
phase from the unenhanced phase was highly predictive of RCC [23]. During the 
corticomedullary phase, normal renal parenchyma will measure approximately 200-300 HU, 
which is greater than the typical post-contrast CT number of an RCC mass.  
Imaging in the post-contrast phase may not allow for distinct differentiation of 
hyperattenuating cysts from renal neoplasms. Acquiring a delayed phase can demonstrate contrast 
washout, or de-enhancement, associated with a diagnosis of vascularity of the mass, allowing for 
differentiation of hyperattenuating cysts from renal neoplasms [24].  
1.2.2 Angiomyolipoma  
 Accurate classification of renal masses is essential to prevent unnecessary medical 
intervention. As previously discussed, RCC is a dangerous disease and should be completely 
resected from the kidney when present. But there are some masses, commonly referred to as 
pseudotumors, which can mimic RCC on unenhanced CT scans. An example of a pseudotumor is 
angiomyolipoma (AML), which is the most common benign tumor of the kidney [25]. AML is 
commonly diagnosed by the detection of fat and the measurement of CT numbers on unenhanced 
CT scans. However, in approximately 4.5% of cases the mass is “lipid-poor” and no fat can be 
visualized on CT [26]. In these cases, AML is commonly suspected as being RCC and is treated 
unnecessarily. Thus, the ability of an unenhanced CT image to accurately reflect fatty 
characteristics of a mass is crucial.  
1.3 Virtual Unenhanced Imaging  
The material decomposition capability provided by DECT allows for the estimation of 
the amounts of two basis materials contained within each voxel of an image. An example of such 
a material basis pair is water and iodine. Virtual Unenhanced (VUE) imaging extends basis 
material decomposition to create a virtual pre-contrast CT dataset from a DECT acquisition. 
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Conceptually, basis pair material decomposition is performed into water and iodine projections, 
and then the calculated iodine concentration is removed and replaced with a suitable material 
[27]. In the VUE implementation, the material suppressed iodine (MSI) algorithm (General 
Electric Healthcare, Milwaukee, WI) estimates the volume of iodine contrast contained within 
each voxel and replaces it with an equivalent volume of blood, which is the material that iodine 
contrast has likely displaced in a post-contrast CT acquisition [27].  While this technique can be 
generalized to decompose an image into an arbitrary number of materials [10], the technique 
employed in VUE image reconstruction is believed to utilize a two-material decomposition 
technique [7].  
This algorithm is based on a model that assumes the materials within each voxel mix to 
form an ideal solution, i.e., the volume of a mixture equals the sum of the volumes of the 
constituent materials [27]. Using this model, the linear attenuation coefficient for each voxel in 
the VUE image at a given energy can be described mathematically as [27]: 
µ(𝐸) = ∑ 𝛼𝑖𝜇𝑖(𝐸)           
𝑁
𝑖=1    Equation 1.3-1 
where 
𝛼𝑖 =
𝑣𝑖
∑ 𝑣𝑗
     ϶     ∑ 𝛼𝑖
𝑁
𝑖=1 = 1           Equation 1.3-2 
Since the materials in each voxel mix to form an ideal solution, the sum of the volume of contrast 
and the volume of blood in a mixture of contrast and blood would equal the volume of the total 
mixture. Based on the assumption that iodine displaces only blood, the volume of blood in the 
VUE image would be set equal to the volume of contrast in the post-contrast image. Therefore, 
the volume of contrast removed from each voxel is replaced with the equivalent volume of blood.
 Since the development of the virtual unenhanced imaging reconstruction technique, many 
potential applications have been investigated. Such applications include: 
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 Replacement of pre-contrast images with virtual non-contrast images in  
o Renal DECT exams, the feasibility of which is the focus of this work  
[3, 7, 9, 28]  
o Liver DECT exams [29, 30] 
o DECT urography for detecting urinary stones [31, 32] 
o DECT cholangiography [33] 
 Utilizing a virtual noncalcium technique in: 
o Detection of posttraumatic bone marrow lesions [34] 
o Detection of bone marrow edema in acute fractures [35] 
 Radiotherapy treatment planning to improve dose calculations [36] 
A prior study has compared a number of patient CT datasets using both true pre-contrast and 
virtual non-contrast datasets in multiphase renal exams with a dual-source DECT technique and 
has shown promising results [9]; however, a careful systematic evaluation of this technique has 
not been completed which is the focus of this work. This study also evaluats a different DECT 
acquisition technique and reconstruction algorithm for generating virtual non-contrast datasets. 
Some prior studies are based on a three-material decomposition algorithm used for VUE image 
reconstruction, whereas this study will focus on a two-material decomposition algorithm [7, 9].  
1.4 Motivation 
There are several potential benefits to be realized from replacing true unenhanced (TUE) 
images with virtual unenhanced (VUE) images during multiphase renal CT exams. The first, and 
perhaps most significant, is the reduction in patient radiation dose. Previous studies have 
demonstrated that reductions in radiation dose can be as great as 35% [9]. Second, eliminating the 
pre-contrast phase would reduce the exam time for each patient and consequently could increase 
patient throughput and clinical efficiency. Finally because VUE images are reconstructed from 
post-contrast images, a pre-contrast scan would no longer need to be registered to the post-
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contrast scans, which would potentially reduce misregistration and differences in partial volume 
averaging between the pre- and post-contrast scans [37].  
These potential benefits motivated this study, which assessed the feasibility of replacing 
TUE images with VUE images reconstructed from post-contrast images acquired using DECT. 
As previously discussed, characterization of renal masses is a complicated and sometimes 
equivocal process, and therefore the quality of VUE images must be carefully assessed to ensure 
that diagnostic quality is maintained.   
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Chapter 2. Hypothesis 
2.1 Statement of Hypothesis  
Classification and quantitative evaluation of renal lesions is not significantly different when using 
virtual unenhanced images (VUE) in place of true unenhanced images (TUE) based on a p-value 
of 0.05. Additionally, classification of images based on enhancement measurements will not be 
different when using VUE images versus TUE images for the baseline measurement across a 
wide range of clinical scenarios based on a posterior probability of 0.05 for negative significance 
and 0.95 for positive significance using a mixed effects model.  
2.2 Research Approach 
In order to test this hypothesis, the project was divided into three specific aims. Each aim 
contributed to testing the stated hypothesis.  
Specific Aim 1: A retrospective study of 60 patient exams was conducted for qualitative and 
quantitative evaluation of VUE and TUE images.  
 Sub aim 1.1: Three radiologists were presented with VUE and TUE images for 
qualitative evaluation. The results were analyzed with a Bayesian Hierarchical 
model to determine if VUE images were significantly different from TUE images.   
 Sub aim 1.2: VUE images were compared to TUE images by using quantitative 
measurements of specific regions of interest in each of the 60 unique patient exams. 
These regions of interest included liver, aorta, spleen, spine, cystic lesions (if 
present), subcutaneous fat, and the renal cortex and medulla. The results were 
compared using a paired t-test. 
Specific Aim 2: Characterization of lesions using VUE images compared to TUE images 
was assessed using a set of three patient-mimicking phantoms. These phantoms were used to 
acquire an extensive data-set for the comparison of lesion characterization in each under 
varying conditions. 
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 Sub aim 2.1: Three phantoms were constructed specifically for this research project 
to represent patients of small, medium, and large sizes.  
 Sub aim 2.2: The medium phantom was used to acquire images with a fixed 
configuration (i.e., one lesion size in a specific position in the SFOV) and variation 
only in the GSI protocol used. The acquired images were evaluated to determine up 
to five candidate GSI protocols that were to be used for evaluation of the medium 
and small phantoms. This same process was repeated to determine candidate GSI 
protocols for evaluation of the large phantom.   
 Sub aim 2.3: All phantoms were imaged in different configurations using the GSI 
protocols identified in Sub aim 2.2. The variables in configuration setup included 
location of the lesion within the SFOV, lesion size, phantom size, image thickness, 
contrast concentration, and selected GSI protocol. The results were analyzed using a 
Bayesian Hierarchical model.  
 Sub aim 2.4: A set of up to 3 optimal clinical GSI protocols will be identified and 
recommended for clinical use in clinical multiphase DECT for renal evaluation, if 
differing from current clinically used protocols. 
Specific Aim 3: The effect of ASIR (adaptive statistical iterative reconstruction) on VUE CT 
number measurements was evaluated.  
 Sub Aim 3.1: A subset of images acquired in Sum Aim 2.3 were used to reconstruct 
VUE images with varying levels of ASIR under varying conditions. The variables in 
configuration setup included location of the lesion within the SFOV, lesion size, 
phantom size, image thickness, contrast concentration, and selected GSI protocol. 
The variation in reconstruction technique involved application of 0%, 60%, and 
100% ASIR levels for each phantom configuration. The results were analyzed using 
a mixed effects model. 
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Chapter 3. Methodology 
3.1    Specific Aim 1 Methods 
 Virtual unenhanced images were reconstructed from DECT data sets for 60 consecutive 
patient exams using version 2.0 of the GE AW Server. A single source multi-detector row GE 
Discovery CT750HD (General Electric Healthcare, Milwaukee, WI) scanner was used to acquire 
the patient exams, an example of which is shown in Figure 2. This system consisted of one X-ray 
tube which rapidly switched between two energy spectra and a corresponding 64-channel detector 
with 0.625 mm channel width. The DECT data set was then loaded onto the dedicated DECT 
post-processing workstation (AW Server, version 2.0; General Electric Healthcare) for 
reconstruction. The multi-material decomposition algorithm, referred to as Material Suppressed 
Iodine (MSI), was then applied to post-contrast images in the GSI Volume Viewer (General 
Electric Healthcare, Milwaukee, WI), to reconstruct the VUE images. Each image was 
reconstructed at 3.75 mm thickness, 2.5 mm interval, and a DFOV identical to that used to 
acquire the TUE. VUE images were reconstructed for all 60 patient cases, for a total of 120 
images (60 VUE and 60 TUE) for analysis.  
 
Figure 2. GE Discovery CT750HD Scanner 
 60 standard of care patient examinations with an indication of pancreatic lesions were 
consecutively selected for retrospective analysis. The demographics of the patients examined are 
given in Table 2.  
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 N Mean age (yrs) Age range (yrs) Mean BMI (kg/m2) 
Male 33 63 39 - 77 25.7 
Female 27 60 33 - 79 27.1 
Total 60 62 33 - 79 26.3 
Table 2. Demographic Information for Patients used in Retrospective Study 
An unenhanced scan of each patient was first acquired using 120 kVp with tube current 
modulation, a pitch of 0.984, and a gantry rotation time of 0.8 s. The iodine contrast agent was 
administered intravenously at an injection rate of 4cc/sec (125 cc total) with a delay of 40 seconds 
and a DECT dataset was acquired during the arterial phase. A pitch of either 0.516 or 0.984 was 
used with a corresponding gantry rotation time of 0.5 s or 0.8 s, respectively. The DECT dataset 
was acquired using beam energies of 80 kVp and 140 kVp. The interleaved high and low 
projections were used to generate water and iodine attenuation maps, which were then used for 
VUE image reconstruction. 
 The patient cases used for Specific Aim 1 were standard of care, and were analyzed 
retrospectively. As a consequence the raw data were not available for image reconstruction; 
therefore it was not possible to exactly match reconstruction parameters between TUE and VUE 
images. This was problematic in particular because different reconstruction kernels and different 
levels of iterative reconstruction (Adaptive Statistical Iterative Reconstruction [ASIR], General 
Electric Healthcare) were applied to the TUE images and the DECT dataset. TUE images were 
reconstructed with the SOFT kernel and 60% ASIR, whereas the VUE images were reconstructed 
with the STANDARD kernel and 0% ASIR. This variation in reconstruction is a limitation of the 
study, as it may have affected the qualitative comparison of VUE to TUE images.  
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3.1.1 Sub aim 1.1 
A qualitative comparison of VUE and TUE images was conducted with three experienced 
radiologists. Images were blinded as to method of reconstruction and presented to each 
radiologist individually. Each radiologist was asked to complete a questionnaire for each image 
presented. The full survey presented with the associated instructions are provided in Appendix 
6.1. The survey evaluated the following image characteristics using a Likert scale: 
1. Visualization of major vessels (considering hepatic, portal, and renal veins in particular) 
2. Visually sharp reproduction of the pancreatic contour 
3. Visualization of calcifications 
4. Depiction of liver parenchyma, e.g., ability to determination of the degree of fatty 
infiltration  
5. Visualization of adrenal glands 
6. Corticomedullary differentiation 
A random subset of 15 patient cases was selected to be repeated to quantify intra-observer 
variability. The complete set of images presented to each radiologist included 150 images in total 
(60 VUE and 60 TUE unique images, as well as 15 repeated VUE images and the corresponding 
15 repeated TUE images). Each radiologist completed the retrospective evaluation in multiple 
sessions to minimize fatigue. The data from this study were analyzed using a Bayesian 
Hierarchical model.  
3.1.2 Sub aim 1.2 
A quantitative comparison of the TUE and VUE images was conducted using the version 
2.0 of the GE AW Server. Each TUE image was non-rigidly registered to the corresponding VUE 
image prior to ROI placement using the “Integrated Registration” feature of the post-processing 
workstation. ROI measurements were made in the following anatomical regions in all images: 
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 Liver  
 Abdominal aorta  
 Inferior vena cava 
 Spleen 
 Spine 
 Renal medulla 
 Renal cortex 
 Cystic lesion (if present) 
 Subcutaneous fat 
Notice that the selected regions were anatomically different, comprising tissues of differing 
density and attenuation properties for analysis of the impact of the MSI algorithm on tissues with 
varying amounts of iodine contrast on board. Theoretically the spine and subcutaneous fat should 
be minimally affected by the MSI algorithm because these regions generally do not uptake iodine 
contrast.  
 Regions of interest placed in each tissue ranged in area from 30 mm 2 to 700 mm2, 
depending on the size of the anatomical structure. Examples of ROI placement are shown in 
Figure 3. The data from this study were analyzed using a student’s paired t-test.  
  
Figure 3. Example ROI placement for quantitative measurements, from left to right: (left 
image) liver, spine, spleen; (center image) renal cortex, renal medulla, abdominal aorta, 
subcutaneous fat; (right image) cystic lesion 
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3.2    Specific Aim 2 Methods 
A phantom study was conducted to assess the accuracy of lesion characterization when 
using VUE images in place of TUE images. Phantoms were constructed at the MD Anderson 
Center for Advanced Biomedical Imaging (CABI) machine shop. The phantoms were used to 
acquire an extensive data-set for lesion characterization across varying conditions. The GE 
Discovery CT750HD DECT scanner with Gemstone Spectral Imaging (GSI) capability located at 
CABI was used for all data acquisition and the GE AW workstation was used for all image 
processing. 
 3.2.1 Sub aim 2.1 
Three phantoms were constructed to represent patients of small, medium, and large sizes. 
Each phantom contained the following: 
 Delrin rod 3.67 cm in diameter to mimic patient spine  
 Insert for PMMA hollow sphere 1.0 cm in diameter located to the right of the spine  
 Insert for 3 PMMA hollow spheres of diameter 1.0, 2.0, and 3.0 cm located in the 
periphery of the phantom. The three different size inserts allowed for assessment of 
variation of lesion size on enhancement accuracy. Additionally, the 1.0 cm sphere was 
compared to the 1.0 cm sphere located in the right kidney region for evaluation of the 
effect of lesion position within the field of view (FOV) enhancement accuracy.  
 Insert for PMMA cylinder 1.0 cm in diameter located to the left of the spine  
The distance of each insert from the Delrin rod (spine) varied depending on patient size. All 
phantoms were composed of four elliptical plates that were 5 cm thick, yielding a total length of 
20 cm for all phantoms. An axial section of the design for each phantom, including the distance 
of each insert from the Delrin rod, is given in Appendix 6.2.  
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Phantom Size 
Phantom Dimensions (cm) 
Major 
Axis 
Minor 
Axis 
 
Small 28.3 17.4 
Medium 36.1 22.2 
Large 47.9 29.4 
Table 3. Phantom Dimensions 
The dimensions of each phantom are displayed in Table 3 and were based on the 5th 
(small), 50th (medium), and 95th (large) percentiles of the United States population from the 
People-Size 2008 visual anthropometry software (Open Ergonomics Ltd, Leicestershire, UK). An 
example CT image of the medium phantom with the 3 cm outer sphere, 1 cm inner sphere, and 1 
cm rod insert in place is included in Table 3. Each phantom was composed of four 5 cm thick 
high density polyethylene (HDPE) elliptical plates. Three sets of the two central plates for each 
phantom were constructed to accommodate the 1, 2, and 3 cm outer spherical inserts, which 
simulated variation in lesion size, pictured in Figure 4.  
  
Figure 4. The three sets of exchangeable phantom plates for the small phantom, which 
accommodated spherical lesions of varying diameter. Each set served as the center two 
plates of the phantom, and could be exchanged to allow for different lesion sizes 
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Figure 5. Custom designed small phantom fully assembled (left image), the center two plates 
(center image), and half assembled (right image) 
3.2.2 Technical Notes 
3.2.2.1 Relationship between CT number and iodine concentration  
 For phantom experimentation, a relationship between CT number and iodine 
concentration was determined. Variation in energy spectra across CT scanners makes analytic 
calculation of this relationship difficult; therefore it was determined experimentally. Previous 
experiments had shown that for a 120 kVp beam the relationship between iodine concentration 
and CT number can be expressed as [38]: 
𝐼𝑜𝑑𝑖𝑛𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (
𝑚𝑔
𝑚𝐿⁄ ) = 0.0365 ∗ (𝐶𝑇 𝑛𝑢𝑚𝑏𝑒𝑟) − 0.85   Equation 3.2.2.1-1 
 Using this relationship as a baseline for developing the methodology for this experiment, 
six Optiray 320 (Mallinckrodt Pharmaceuticals, St. Louis, MO) and water mixtures were chosen, 
as given in Table 4. The medium phantom with the 3 cm diameter insert, which had a volume of 
14.1 mL, was used for each trial. The iodine concentration for each mixture was calculated using 
the volume of the insert, as well as the concentration of Optiray 320, which contained 320 mg/mL 
organically bound iodine. The volume of Optiray 320 was measured using a 2 mL volumetric 
pipette, which had a reported uncertainty of ± 0.01 mL. Images were acquired with the GE 
HD750 DECT scanner using the GSI-37 DECT protocol (medium body filter, 0.8 sec rotation 
time, 40 mm beam width, 0.984 pitch, 260 mA, and a CTDIvol of 10.99 mGy) and a 2.5 mm 
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image thickness. For each trial, the mean CT number (HU) and standard deviation were recorded 
from a circular region of interest (ROI) of approximately 150 mm2 drawn in the center of the 3 cm 
sphere in the central axial image through the sphere. The ROI was propagated through the two 
images superior and inferior to the central image for a total of five ROI measurements on 
consecutive slices. The average of these measurements was computed and linear regression was 
used to calculate the relationship between CT number (HU) and iodine concentration (mg/mL) 
for the CT scanner used in this study.  
Trial Optiray (mL) 
Concentration 
of Optiray by 
volume (%) 
Concentration 
of Water by 
volume (%) 
Iodine 
Concentration 
(mg/mL) 
1 0.14 0.99 99.01 3.17 
2 0.28 1.98 98.02 6.34 
3 0.42 2.97 97.03 9.51 
4 0.56 3.96 96.04 12.68 
5 0.70 4.95 95.05 15.84 
6 0.84 5.94 94.06 19.01 
Table 4. Iodine concentrations used for experimentation 
 
3.2.2.2 Phantom set-up verification 
 As discussed in section 1.2.1, renal cell carcinoma (RCC) has been shown to enhance 
from the range of 20-70 HU in the pre-contrast image to approximately 110 HU in the 
corticomedullary phase [22, 23], while normal kidney parenchyma enhances from approximately 
30 HU to 200-300 HU. As a result, in an actual patient exam TUE images will be obtained when 
the renal mass has an attenuation approximately equal to or greater than the surrounding renal 
tissue, and VUE images are reconstructed from DECT data acquired when the renal mass has 
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attenuation less than that of the surrounding normal tissue. In practice, the DECT image is 
acquired with the renal mass in a positive enhancing background, whereas with the phantom 
constructed for this study simulated renal masses in a negative contrast background. The potential 
impact of the differences between clinical CT and the phantom study was evaluated using the 
Jaszczak Phantom (Biodex, Shirley New York) imaged in two configurations, one mimicking the 
expected patient scenario and the other mimicking the phantom scenario, the details of which are 
given in Table 5. The Jaszczak phantom was configured with three hollow spheres of different 
sizes (Table 5 and Figure 6). The relationship between CT number and iodine concentration 
determined experimentally (section 4.2.1.1) was used to calculate the amount of iodine contrast 
necessary to achieve the desired CT number.  
 Sphere Background 
 
Experiment 1: 
Patient set-up 
Iodine-water 
mixture (100 HU) 
Iodine-water 
mixture (250 HU) 
Experiment 2: 
Phantom set-up 
Iodine-water 
mixture (100 HU) 
Water (0 HU) 
Table 5. Jaszczak Phantom Experiment 
   
Figure 6. Example images from the Jaszczak phantom experiment. An expected patient 
scenario for post-contrast imaging in the corticomedullary phase was simulated (left), as 
well as the phantom set-up (right) 
DECT Images were acquired with the GE HD750 scanner using the GSI-11 DECT 
protocol (medium body filter, 36 cm DFOV, 0.8 sec rotation time, 40 mm beam width, 600 mA, 
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0.984 pitch, and a CTDIvol of 26.70 mGy) and a 2.5 mm image thickness. VUE images were 
reconstructed from all DECT images. For each experiment, the mean CT number (HU) and 
standard deviation were recorded from a circular region of interest (ROI) of approximately 150 
mm2 for the 31.8 mm diameter sphere and 100 mm2 for the 25.4 mm diameter sphere drawn in the 
central axial image through the sphere. The ROI was propagated through the two images 
immediately superior and inferior to the central image to yield ROI measurements on five 
consecutive images.  
 
3.2.3 Sub aim 2.2 
A single configuration was selected for imaging the medium phantom, so as to bridge the 
retrospective study to the phantom study. The parameters selected were informed by techniques 
used to acquire the unenhanced and DECT images in the retrospective study, and are listed in 
Table 6. All available GSI protocols on the GE CT750HD scanner for the medium size bowtie 
were used for image acquisition. A complete list of the presets used is given in Appendix 6.3. 
Parameter 
Medium 
Phantom (DECT) 
Medium 
Phantom (TUE) 
Image thickness 5.0 mm 5.0 mm 
DFOV 400 400 
Pitch 0.984 0.984 
kVp, mAs GSI protocol dependent 120, 150 
Lesion diameter 3 cm 3 cm  
Table 6. Imaging parameters for the single phantom configuration used for comparison of 
GSI protocols 
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 The phantom inserts were filled with an Optiray 320 and water mixture with 3.38 mg/mL 
iodine concentration to simulate approximately 80 HU enhancement for DECT image acquisition, 
and with water only for TUE image acquisition. The following equation was used to convert the 
calculated iodine concentration necessary to simulate a given CT number to Optiray 320 
concentration: 
𝑶𝒑𝒕𝒊𝒓𝒂𝒚  (𝒎𝑳) =
𝒊𝒐𝒅𝒊𝒏𝒆 (𝒎𝒈 𝒎𝑳⁄ )∗𝒕𝒐𝒕𝒂𝒍 𝒗𝒐𝒍𝒖𝒎𝒆 (𝒎𝑳) 
𝟑𝟐𝟎 (𝒎𝒈/𝒎𝑳)
                   Equation 3.2.3-1 
VUE images were reconstructed from DECT images and compared to TUE images acquired with 
water only in the inserts. The intention of this experiment was to determine which GSI protocol 
produced VUE images in which measured CT numbers most closely matched those in TUE 
images, and then to use this information to identify 3-5 candidate protocols for further evaluation. 
CT numbers and their associated standard deviations were measured from a circular ROI placed 
in the center of each insert as well as in the spine of the phantom for VUE and TUE images. The 
dimensions of the ROIs placed for each image are given in Table 7.  
ROI Location ROI size (mm2) 
Center insert 14.4 
Peripheral 
insert 
1 cm 14.4 
2 cm 70-80 
3 cm 140-150 
Hollow rod insert 6.0 
Delrin rod 320-350 
Table 7. Dimensions of ROI placement for each measurement location in TUE and VUE 
images 
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3.2.4 Sub aim 2.3 
 Phantoms were imaged in different configurations using the GSI protocols identified in 
Sub Aim 2.2, which are listed in section 4.2.2. The following parameters were varied to assess the 
effect of patient specific factors on the accuracy of enhancement measurements assessed using 
DECT: 
 Patient size: As discussed previously, variation in patient size was evaluated by imaging 
three phantoms of different sizes. The dimensions of each phantom are listed in Table 3. 
 Lesion size: Hollow spheres of 1 cm, 2 cm, and 3 cm diameter were used to simulate 
variation in lesion size.  
   
Figure 7. Variation in lesion size for the small phantom 
 Position within the field of view (FOV): Each phantom also contained a 1 cm hollow 
sphere near the spine insert in addition to the 1 cm sphere mentioned in the previous 
section, which was located in the periphery of the phantom. These spheres were used to 
study the effect of position within the FOV on enhancement accuracy. The distance of 
each lesion from the Delrin rod increased proportionally with increasing phantom size.  
 
Figure 8. Variation of position of the lesion within the FOV 
“Periphery” 
“Center” 
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 GSI protocol: As determined in Sub Aim 2.2, GSI protocols 10, 11, 16, and 29 were used 
for the small and medium phantoms and GSI protocols 10, 12, 22, 36 were used for the 
large phantom to study the impact of GSI protocol on quantitative accuracy of DECT. 
The parameters associated with each of these protocols are listed in Table 19. 
 Enhancement magnitude: The purpose of varying contrast concentration was to assess 
VUE enhancement accuracy across a wide range of simulated clinical scenarios. The 
clinical scenarios used to vary iodine concentration are detailed in the following sections.  
The most common method for classifying renal lesions is the Bosniak criteria [19]. These 
guidelines provide a method for categorizing cystic lesions based on several characteristics 
including enhancement of the lesion, which has been stated to be the most important criterion 
used in determining surgical from non-surgical renal masses [17]. Consequently, it is crucial that 
CT numbers measured in pre- and post-contrast images are accurate. This motivated the 
incorporation of variation in iodine concentration as a parameter of interest in the phantom study. 
Five clinical scenarios were simulated, each of which are detailed in the following sections. 
 For each simulation, the concentration of Optiray 320 necessary was determined using 
the relationship between CT number and iodine concentration given in 4.2.1.1. Optiray 320 was 
measured for each solution using a 2 mL volumetric pipette with an associated uncertainty of ± 
0.01 mL. Images were then acquired using the GE HD750 DECT scanner. VUE images were 
reconstructed from DECT data and then CT number, as well as the associated standard deviation 
of the measurement, was recorded from ROI placement in various regions of the phantom. The 
dimensions of the ROIs for each measurement location are listed in Table 7. The data were 
analyzed using a mixed effects model that accounted for both fixed and random effects, which is 
further discussed in 4.2.4. In Clinical Scenarios 1 and 2, VUE images were reconstructed from 
DECT images and were compared to TUE images acquired using SECT. A conceptual 
explanation of the experimental design for Clinical Scenarios 3-5 is given in Table 8. Further 
explanation regarding the solutions used to simulate each scenario is detailed in the following 
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sections. An example of the image acquisition matrices for SECT images and for DECT is 
provided in Appendix 6.4.  
Pre-contrast Post-contrast Analysis 
TUE 
(SECT) 
Acquired as 
“baseline” with 
no Optiray 320 
SECT 
Acquired with the 
specified concentration 
of Optiray 320 
Enhancement   = 
SECT – TUE 
VUE 
(DECT) 
Reconstruction 
from DECT post-
contrast images 
DECT 
Acquired with the 
specified concentration 
of Optiray 320 
Enhancement   = 
DECT – VUE 
Table 8. Conceptual description of the experiment design for Scenarios 3-5 
Scenario 1 
A fatty lesion was simulated to mimic angiomyolipoma (AML), which is a non-surgical 
renal pseudotumor that can mimic a mass requiring surgery, such as renal cell carcinoma. This 
simulation allowed for assessment of the ability of VUE images to accurately represent fatty 
lesions. As discussed in section 1.2.2, this simulation represented a clinical scenario in which it is 
crucial to distinguish AML from RCC to avoid unnecessary intervention.  
The AML lesions were simulated by filling the inserts for the phantom with vegetable oil, 
yielding a CT number of approximately -100 HU. All images were acquired with only vegetable 
oil in the spheres.   
  
Figure 9. TUE (left) and VUE (right) of small phantom for Scenario 1 
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Scenario 2 
This scenario, along with those to follow, served to simulate the categories of the Bosniak 
criteria, which are detailed in Table 1. Category I of the Bosniak criteria describes a benign 
simple cyst that measures water density and does not enhance [21]. Simple benign cysts were 
simulated by filling the phantom inserts with distilled water. All images were acquired with only 
distilled water in the spheres.   
  
Figure 10. TUE (left) and VUE (right) of small phantom for Scenario 2 
Scenario 3 
 Category II-IIF of the Bosniak criteria describes a benign cyst in which enhancement 
may be perceived, and those in category IIF require follow-up studies to prove benignity [21]. In 
order to simulate a lesion that is likely benign, but requires further investigation to prove 
benignity, such as a category IIF cyst, a baseline attenuation of 20 HU was simulated to represent 
the pre-contrast phase of imaging. A 20 HU baseline was chosen because it represented a 
borderline measurement for identification of RCC on a TUE image, which typically measures in 
the 20-70 HU “danger zone” in the pre-contrast imaging phase [22]. For post-contrast simulation, 
Optiray 320 was added to the solution to simulate a small amount of enhancement. For a lesion in 
this category, enhancement may be perceived but would be minimal [21].  As discussed in section 
1.2, it was previously believed that 10 HU was the threshold for enhancement determination, but 
with the advent of helical CT it was proposed that this threshold be increased to 15 or even 20 
HU, and there is currently no universal agreement on this matter [16, 17]. Considering this, two 
enhancement scenarios were simulated for this experiment to represent a low “perceived” 
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enhancement of 5-10 HU and a borderline, or intermediate, enhancement of approximately15-20 
HU.  
 The baseline images for this scenario were acquired with an apple juice and water 
mixture to simulate an attenuation of 20 HU. Apple juice was chosen for simulation in this and 
the subsequent scenarios as a surrogate for blood because it has an effective atomic number, 
density, and CT number that is very similar to blood. Optiray 320 was then added to the mixture 
to simulate each enhancement scenario, and the SECT and DECT post-contrast images were 
acquired. The Optiray 320 concentrations necessary to simulate these levels of enhancement were 
calculated based on the relationship determined in section 4.2.1.   
  
Figure 11. TUE (left) and VUE (right) of small phantoms for Scenario 3, VUE image 
pictured was reconstructed from the intermediate enhancement DECT image 
Scenario 4 
 A Bosniak Category III lesion is intermediate that requires further work-up, for example 
a lesion measuring approximately 40 HU on a pre-contrast image and exhibiting slight 
enhancement in post contrast images. An attenuation of 40 HU was chosen for this scenario as 
well as for Scenario 5 because a recent study has shown that the attenuation of renal neoplasms as 
measured by a radiologist was on average 38.4 HU [39]. Two enhancement scenarios were 
simulated to represent low enhancement (5-10 HU) and intermediate enhancement (15-20 HU). 
As previously stated, the aim of scenarios 3-4 was to simulate borderline lesions for comparison 
of TUE to VUE as the baseline image for enhancement measurements, which is where the 
accuracy of an enhancement calculation is the most crucial.   
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The baseline SECT images were acquired with an apple juice/water mixture (with a CT 
number of approximately 40 HU) in the inserts and the DECT images were acquired with Optiray 
320 added to the mixture, as described previously.  
   
Figure 12. TUE (left) and VUE (right) of small phantom for Scenario 4, VUE image 
pictured was reconstructed from the low enhancement DECT image 
Scenario 5 
Bosniak Category IV describes a lesion that is clearly malignant and enhances substantially 
[21]. A lesion in this category will exhibit high vascularity and consequently demonstrate 
substantial uptake of iodine contrast in post-contrast imaging, resulting in significant 
enhancement. An enhancement of approximately 40-50 HU was chosen for simulation because it 
demonstrates definitive enhancement and is in the range of typical enhancement of RCC. A 
previous study has shown that clear cell renal carcinoma (cRCC) and papillary renal cell 
carcinoma (pRCC) enhance to a mean of 149 and 91 HU, respectively, in the corticomedullary 
phase and 95 and 71 HU, respectively, in the nephrographic phase [40].  
This was simulated by using apple juice/water mixture for the baseline unenhanced image. 
Optiray 320 contrast was then added to the mixture to result in a total attenuation of 80 HU, 
which corresponded to an enhancement of 40 HU.  
   
Figure 13. TUE (left) and VUE (right) of small phantoms for Scenario 5 
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For each scenario, CT number and image noise were measured in all inserts. The data 
collected were analyzed using a mixed effects model, chosen to account for fixed and random 
effects in the study. The details of this model are given in section 4.2.4. A summary of the five 
clinical scenarios simulated is given in Table 9.  
Clinical Scenario TUE baseline (HU) Enhancement (HU) Purpose: 
Fatty lesion -100 None 
Ability to distinguish 
fatty lesions 
Bosniak I 0 None 
Ability to distinguish 
a benign simple cyst 
Bosniak II-IIF 20 5-10, 15-20 
Assess lesion 
enhancement accuracy 
Bosniak III 40 5-10, 15-20 
Bosniak IV 40 40-50 
Table 9. Summary of clinical scenarios for experiments 
 
 An evaluation of the sources of variation in the measurements was necessary to account 
for random effects in the mixed effects model. The potential sources of random error were 
identified as preparation of the solutions and phantom set-up (σP), scanner variability (σS), 
variation between images in each acquisition (σM), and variation across the ROI, or quantum 
noise (σN).  
 Variation in preparation of the solutions (σP) was controlled for in the design of the 
experiments. For each prepared solution all images needed for all phantom configurations for that 
particular solution were acquired using a single preparation of inserts. That is, one mixture was 
created and used for all imaging; therefore limiting uncertainty due to systematic error, which 
was associated with the use of a volumetric pipette to measure the Optiray 320 concentrations, 
which had a reported uncertainty of ± 0.01 mL.  
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The random error of the CABI CT scanner (σS) was evaluated by using the QC data 
collected daily on the scanner over the course of two months. This analysis only considered the 
CABI CT 750HD scanner because it was the only scanner used for image acquisition in these 
experiments. The mean of the CT number measurements recorded for water each day was 
calculated, as well as the associated standard deviation.  The standard deviation was then used to 
calculate the standard error (σS). 
 Variation between ROI measurement locations within the simulated lesion (σM) was 
considered as a source of random error. This was quantified by randomly selecting images from 
the experiment, and repeating CT number measurements 10 times in each region of interest. The 
standard deviation of the mean was computed, and then used to calculate the standard error. The 
standard error was < 0.1 in all cases, and was therefore considered to be negligible. This 
conclusion is expected considering the size of the ROI placed relative to the diameter of the 
spherical inserts constrained variation. Note that image-to-image variation was not considered 
because of the size of the spherical inserts relative to the 5.0 mm thickness of the images. Given 
that measurements were made in the 1 cm sphere for all images, there was only one image in each 
case where measurements could be made with minimal partial volume effect.  
The SE associated with quantum noise (σN) was quantified by calculating the standard 
error of the mean CT number. For Scenarios 1 and 2, this was done using the recorded the 
standard deviation of each ROI measurement and the calculated number of pixels in each ROI. 
This could not be done for Scenarios 3, 4, and 5 because the result used for analysis was the 
difference between pre- and post- contrast measurements, i.e. the enhancement value. Notice that 
a standard deviation was recorded for each pre- and post-contrast measurement. In order to 
determine σN for these scenarios, the standard error was calculated for each pre- and post-contrast 
measurement and the results were added in quadrature [41]:  
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𝝈𝑵 = √(𝝈𝒑𝒓𝒆)
𝟐
+ (𝝈𝒑𝒐𝒔𝒕)
𝟐
          Equation 3.2.4-1 
 The total variation was then calculated by adding each source of variation in quadrature 
for each measurement. The estimated variation used as the input for random error in the mixed 
effects model is shown in equation 3.2.4-2. 
𝝈𝒕𝒐𝒕𝒂𝒍 = √(𝝈𝑺)𝟐 + (𝝈𝑵)𝟐   Equation 3.2.4-2 
 
3.2.5 Sub aim 2.4 
 The purpose of this sub aim was to determine a set of up to three optimal GSI protocols 
to recommend for clinical DECT image acquisition, which could be used to reconstruct VUE 
images.  This was not done because the results of this study do not support the clinical 
replacement of TUE images with VUE images.   
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3.4    Specific Aim 3 Methods 
An evaluation of the effect of ASIR (adaptive statistical iterative reconstruction) on CT 
number accuracy of the VUE images was conducted. ASIR is a form of iterative reconstruction 
that begins after a first pass of filtered back projection reconstruction is completed, which 
shortens the time of reconstruction as compared to purely iterative techniques. The potential 
benefit driving clinicians to use ASIR is the reduction in noise, which could allow for reduction 
in the mA required to maintain diagnostic image quality, and consequently a reduction in patient 
dose. 
A subset of the images acquired in Sub Aim 2.3 was used for this experiment to assess 
the impact of ASIR levels under varying phantom configurations. The variables selected to be 
assessed for this experiment were informed by observations made from Sub Aim 2.3 data. For 
each phantom configuration used, images were reconstructed with 0%, 60%, and 100% ASIR 
levels. The variables considered for this experiment were: 
• Patient size: small, medium, and large 
• Lesion size: 1 cm and 3 cm 
• GSI protocol: the same protocols used in Sub Aim 2.3 will be assessed in this 
experiment  
• Contrast concentration: 20 HU baseline lesion with 15-20 HU enhancement and 40 
HU baseline lesion with 40 HU enhancement  
• ASIR level: 0%, 60%, 100% 
For each image set acquired CT number and noise were measured on the GE AW workstation in 
the spherical inserts as well as the Delrin rod, which mimics spine. The dimensions of the ROIs 
drawn for measurements are given in Table 7. Results were analyzed using a mixed effects 
model, the details of which are given in section 4.2.4.  
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Chapter 4. Results 
4.1 Specific Aim 1 
 A retrospective analysis of 60 patient cases, with quantitative and qualitative 
comparisons, was conducted to statistically test the feasibility of replacing TUE with VUE 
images.  
4.1.1 Results: Sub Aim 1.1 
The qualitative study was based on a questionnaire given independently to three 
experienced radiologists for a total of 150 images (75 TUE and the corresponding 75 VUE 
images). Figure 14 presents a comparison of the mean scores between TUE and VUE images for 
all radiologists and patient exams for each question. Recall that questions 1-5 were based on a 5 
point scale, and question 6 was based on a 3 point scale.  
 
Figure 14. Comparison of mean TUE and VUE scores 
The results were fitted with a Bayesian Hierarchical model to determine if VUE images 
were non-inferior to TUE images. This model was used for analysis to quantify and account for 
uncertainties, such as inter- and intra-observer variability. The results from this analysis are given 
in Table 10.  
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Question 
Mean 
Difference (β) 
Standard 
Deviation 
95% Credible 
Interval 
Q1 [Visualization of Vessels] -0.514 0.055 (-0.624, -0.408) 
Q2 [Pancreatic Contour] -0.092 0.051 (-0.195, 0.004) 
Q3 [Visualization of Calcifications] -0.127 0.047 (0.216, 0.029) 
Q4 [Depiction of Liver Parenchyma] -0.682 0.052 (-0.786, -0.582) 
Q5 [Visualization of Adrenal Glands] -0.013 0.048 (-0.104, 0.084) 
Q6 [Corticomedullary Differentiation] 1.379 0.039 (1.304, 1.455) 
Table 10. Qualitative study results from the Mixed Effects Model Analysis 
Intra-observer variability was calculated for each radiologist individually. This parameter was 
evaluated based on the random subset of 15 patient exams that were repeated during the study. 
The associated variability is included in the mixed effects model analysis, as described above. 
The results for each radiologist are shown in the figures in Appendix 6.5.  
In addition to the mixed effects model analysis, the Kappa statistics for intra-observer 
variability were calculated for each radiologist and the results are shown in Tables 11-12.  
. 
Radiologist 1  Radiologist 2 Radiologist 3 
Kappa 
Coefficient 
Strength of 
Agreement 
[42] 
Kappa 
Coefficient 
Strength of 
Agreement 
[42] 
Kappa 
Coefficient 
Strength of 
Agreement 
[42] 
Q1 TUE 0.386 Fair 0.079 Slight 0.566 Moderate  
Q2 TUE 0.327 Fair 0.355 Fair 0.634 Substantial 
Q3 TUE 0.339 Fair 0.259 Fair -0.059 
Less than 
chance 
Q4 TUE 0.502 Moderate 0.336 Fair 0.639 Substantial 
Q5 TUE 0.472 Moderate 0.101 Slight 0.348 Fair 
Q6 TUE 1.00 Perfect  1.00 Perfect 1.00 Perfect 
Table 11. Kappa Statistics for Intra-observer Variability (TUE images) 
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Q1 VUE 0.828 
Almost 
Perfect 
0.242 Fair 0.234 Fair 
Q2 VUE 0.712 Substantial 0.571 Moderate 0.526 Moderate 
Q3 VUE 0.298 Fair 0.013 Slight 1.00 Perfect 
Q4 VUE 0.336 Fair 0.828 Almost Perfect 0.4 Fair 
Q5 VUE 0.439 Moderate 0.268 Fair 0.231 Fair 
Q6 VUE 0.545 Moderate 0.268 Fair -0.119 
Less than 
chance 
Table 12. (Continued) Kappa Statistics for Intra-observer variability (VUE images) 
 
Inter-observer variability was characterized between the three radiologists that participated in the 
experiment. This variation between radiologists is also accounted for in the Bayesian Hierarchical 
model, and is shown visually Figure 15.  
 
Figure 15. Inter-observer variability between Radiologists 
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4.1.2 Discussion: Sub Aim 1.1 
The Likert scale for each question presented to each radiologist was discrete in 
increments of 1 point. As a result of the discrete nature of the scale, the VUE images were 
considered to be non-inferior to TUE images if the difference in answers for each question was 
within -0.5 points or greater. This accounted for circumstances in which a radiologist may have 
felt the appropriate response to a given question was, for example 3.5, yet had to choose either 3 
or 4 as the answer, which is a departure of 0.5 from the true perceived difference. The ability to 
recognize an image as TUE or VUE may have influenced the decision, in this example, to choose 
3 or 4. Therefore, the -0.5 threshold was used to control for any potential bias.   
The results of this study are summarized in Table 13, where β represents the mean 
difference between VUE and TUE images calculated using the Bayesian Hierarchical model. 
Recall that this model took into account several factors of variability associated with the study, 
and is therefore not a raw mean difference.  
Question Results 
1. Visualization of major vessels Uncertain (β = -0.514) 
2. Visually sharp reproduction of pancreatic contour Non-inferior (β = -0.092) 
3. Visualization of calcifications Non-inferior (β = -0.127) 
4. Depiction of liver parenchyma Inferior (β = -0.682) 
5. Visualization of adrenal glands Non-inferior (β = -0.013) 
6.  Corticomedullary Differentiation Non-inferior (β = 1.379) 
Table 13. Qualitative Study Results Summary 
In the Bayesian Hierarchical model the variation was calculated to be σ = 0.563 for inter-
observer variability and σ = 0.370 for intra-observer variability. Given that the threshold was 
chosen to be -0.5, it can be seen that these resulting variations are substantial, indicating the 
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necessity for a Bayesian Hierarchical model as opposed to simply using a paired t-test. Notice 
that if the conventional t-test had been used to evaluate these data, these variations would not be 
accounted for and the associated uncertainty with each result would be substantially greater. A 
detailed discussion for the results from each question is given below.  
Question 1, evaluating the visualization of major vessels, resulted in statistical 
uncertainty regarding the difference between VUE and TUE image scores (β = -0.514). This is 
because the 95% credible interval (-0.624, -0.408) contained the -0.5 threshold for differentiation; 
therefore, the difference could be attributed to the limited data set acquired as reflected by the 
standard deviation. The acquired data set could be increased, which would result in a decrease of 
the standard deviation, until the 95% CI no longer contained the -0.5 threshold. In this case, a 
definitive statistical result could be obtained. However, statistical uncertainty implies clinical 
inferiority. An example comparison of the appearance of the hepatic vein in TUE and VUE 
images is provided in Figure 16. The algorithm used to reconstruct VUE images functions by 
estimating the volume of iodine in each voxel and replacing it with an equivalent volume of blood 
[27]; therefore, the visualization of vessels should theoretically be identical for TUE and VUE 
images. As can be seen in Figure 16, this is not the case and the hepatic veins are more clearly 
visible in the TUE image. This is possibly due to inaccurate removal of iodine signal from the 
image or perhaps differences in the levels of iterative reconstruction applied to TUE and VUE 
images. It was noted by each radiologist that visualization of arteries was good, but visualization 
of veins was poor in VUE images.  
   
Figure 16. Appearance of hepatic veins in TUE (left) and VUE (right) images 
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The greatest (negative) difference between scores for VUE and TUE images was for the 
depiction of liver parenchyma (β = -0.682). This is potentially a result of the variation in 
reconstruction techniques used for the TUE and VUE images, as described previously. A 
common complaint among radiologists when answering this question was that the VUE images 
were “grainy” and “noisy”. Iterative reconstruction applied to TUE images but not VUE images 
likely reduced noise and the visual appearance of “graininess”, which was more appealing to the 
radiologists. This motivated the addition of the third specific aim of the project, which 
quantitatively assesses the impact of varying levels of ASIR on enhancement accuracy in VUE 
images.   
Question 6, concerning corticomedullary differentiation yielded the greatest absolute 
difference between VUE and TUE images (β = 1.379), but in for this question VUE images were 
scored greater than or equal to TUE images in all cases. All TUE images were given a score of 1, 
indicating no corticomedullary differentiation, and scores for VUE images ranged from 2-3, 
indicating that there were either slight (2) or extreme (3) differentiation. Corticomedullary 
differentiation typically occurs during the corticomedullary phase of renal enhancement, and is a 
physiologic process that is observed when there is contrast within the cortex that has not yet 
reached the medulla. The corticomedullary differentiation observed in VUE images was a result 
of the MSI algorithm inaccurately removing the substantial amounts of iodine signal present in 
the post-contrast DECT images, which were acquired during the corticomedullary phase of 
enhancement. This differentiation in VUE images is visible even to the untrained eye (Figure 17), 
and is an artifact of the MSI algorithm. Although VUE images were scored higher than TUE 
images, it should be noted that this result implies that VUE images differ from reality (i.e. TUE 
images) where this differentiation is not observed because there is not yet any iodine contrast in 
the cortex. Corticomedullary differentiation could potentially be minimized or eliminated by 
changing the phase in which the DECT data are acquired [43], e.g. by further delaying the post-
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contrast injection scan time and acquiring the DECT data in the nephrographic phase when renal 
enhancement is relatively uniform.  
  
Figure 17. Corticomedullary differentiation in TUE (left) and VUE (right) images 
 The differences between scores for VUE and TUE images for the reproduction of the 
pancreatic contour (β = -0.092) and the visualization of adrenal glands (β = -0.013) were not 
statistically significant. The mean difference in scores, represented by β, between TUE and VUE 
images was minimal. It was expected that the pancreas and adrenal glands would not be affected 
by the MSI algorithm because each does not uptake a significant amount of iodine contrast. Given 
the physiological nature of the pancreas and adrenal glands and considering the vascularity of 
each, it was expected that the scores would not significantly differ between TUE and VUE 
images, and this was experimentally proven to be true.  
 Although the results for the visualization of calcifications (β = -0.127) indicated that 
VUE images were non-inferior to TUE images, this result is misleading. It was noted that each 
radiologist at least once during the study suggested that the scoring for calcifications was in 
essence binary, i.e. it is seen or not seen. There were cases in which calcifications were seen in 
TUE images and not VUE images, and some cases for which the opposite was true (Table 14). 
The few cases where calcifications were seen in VUE but not TUE images is likely attributable to 
the variability of the observer between scoring the TUE and corresponding VUE image 
independently. However, there are more instances where calcifications were seen in TUE images 
and not TUE images. This result is consistent with other studies, and has been referred to in the 
 44 
 
literature as the “subtraction artifact” [9]. The subtraction artifact is a result of the inability of the 
algorithm to accurately distinguish iodine from other materials with high atomic numbers, such as 
calcium. The multi-material decomposition method presumably decomposes a voxel into only 
two materials [7], such as water and iodine, which results in all materials contained in a given 
voxel being represented as some weighted combination of water and iodine. Since calcium has a 
large photoelectric cross-section, a voxel with calcium will be assigned by the algorithm as 
containing some percentage of iodine, which is subtracted when the VUE image is reconstructed. 
This is apparent is a case where calcifications are not as bright in the VUE as in the TUE, or 
when they are not seen at all, as well as when visually comparing the appearance of the spine 
between VUE and TUE images. 
 
Number of 
instances 
calcifications 
were seen in TUE 
but not VUE 
Number of 
instances 
calcifications 
were seen in VUE 
but not TUE 
 
Radiologist 1 7 1 
Radiologist 2 12 2 
Radiologist 3 11 4 
Table 14. Comparison of instances in which calcifications were not seen in one of the images 
Although there were cases where calcifications were seen in VUE but not TUE, this 
occurred much less often than visualization in TUE but not VUE. When considering these cases 
of visualization in VUE but not TUE one should consider the large variations calculated in the 
mixed effects analysis for inter- and intra-observer variability (σ = 0.563 and 0.370, respectively). 
However, the number of instances where calcifications were seen in TUE but not VUE is 
substantial, even considering these sources of variation, and is likely not attributable to these 
sources of variability. This result instead likely reflects an artifact of the algorithm, which 
subtracts calcium signal due to the representation of calcium as a weighted combination of water 
and iodine.  
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4.1.3 Results: Sub Aim 1.2 
 The quantitative study was based on CT number measurements in the patient exams used 
in the qualitative study. A plot of the average CT number measured in each region of interest can 
be found in Figure 18, and the corresponding quantitative comparison can be found in Table 15.  
 
Figure 18. Comparison of average HU measured in TUE vs. VUE 
 
TUE Mean CT 
number (HU) 
VUE Mean CT 
number (HU) 
Spleen 41.4 47.6 
Liver 51.2 52.3 
Spine 155.3 82.2 
Aorta 35.9 44.8 
Cortex 27.5 40.4 
Medulla 29.1 28.1 
Subcutaneous Fat -99.2 -95.6 
IVC 29.4 39.2 
Cystic Lesion 16.0 15.1 
Table 15. Quantitative results: Average CT numbers 
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 The fraction of cases where the absolute difference between TUE and VUE 
measurements was greater than 10 HU was plotted to visualize where the greatest differences 
occurred, as shown in Figure 19.  
 
Figure 19. Absolute difference in CT number between TUE and VUE images 
 
The data collected from this study were analyzed using a student’s paired t-test. The ± 6 
HU tolerance at 120 kVp for water required by the manufacture for the 750HD DECT scanner 
was used as the basis for the determination of a relative threshold. The ± 6 HU tolerance was 
converted into an uncertainty about the linear attenuation coefficient of water at 70 keV: 
𝝁 = 𝟎. 𝟏𝟗𝟒𝟖 ± 𝟎. 𝟎𝟎𝟏𝟐 𝒄𝒎
𝟐
𝒈⁄      Equation 4.1.3-1 
This equates to a tolerance of ± 0.6% about water. The average CT number measured on the TUE 
images for each area of interest was converted to a linear attenuation coefficient, and a ± 0.6% 
threshold was calculated about each. The average of the upper and lower tolerances (i.e. -0.6% 
and +0.6%) was calculated, converted back to CT number (HU) and used as the threshold for 
each organ. The thresholds used for the t-test are given in Table 16. 
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Mean CT 
number (HU) 
µ (cm-1) 
0.6% tolerance 
in µ (cm-1) 
± HU 
Spleen 41.4 0.203 0.0012 6.25 
Liver  51.2 0.205 0.0012 6.31 
Spine 155.3 0.225 0.0014 6.93 
Aorta  35.9 0.202 0.0012 6.22 
Cortex 27.5 0.200 0.0012 6.16 
Medulla 29.1 0.201 0.0012 6.17 
Fat -99.2 0.176 0.0011 5.41 
IVC 29.4 0.201 0.0012 6.18 
Table 16. Determination of Threshold of differentiation 
The results of this study are summarized in Table 17 below. A p-value of < 0.05 indicated 
that VUE images were non-inferior to TUE images, and was calculated based on the threshold 
determined for each area of interest. A p-value of ≥ 0.05 indicated that VUE images were inferior 
to TUE images. 
Organ P-value 
95% CI for the 
difference 
Results 
Spleen 0.815 (-7.53, -5.01) Inferior 
Liver < 0.001 (-0.85, 3.05) Non-inferior 
Spine 1.000 (64.12, 82.23) Inferior 
Aorta 0.999 (6.57, 11.13) Inferior 
Cortex 1.000 (10.69, 15.25) Inferior 
Medulla < 0.001 (-0.82, 2.86) Non-inferior 
Subcutaneous Fat 0.676 (1.71, 5.11) Inferior 
Inferior Vena Cava 0.999 (-7.42, 12.24) Inferior 
Table 17. Quantitative results summary 
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4.1.4 Discussion: Sub Aim 1.2 
 The thresholds used for statistical analysis were based on physics principals, and 
therefore leave open the question of the clinical relevance of the results. Consider, for example, 
the results for the spleen (based on a ± 6.25 HU threshold). The t-test indicated that VUE images 
are inferior to TUE images, but the 95% confidence interval (CI) indicates that VUE images will 
measure within -7.53 HU of TUE images. To assess the clinical relevance of these results, an 
evaluation of the implications of the variation in CT number on a grayscale image was conducted. 
The purpose of this assessment was to determine if the variation in CT number between TUE and 
VUE images, based on the calculated 95% CI, would even be perceivable to a radiologist.  
 The evaluation was done for a window width/ window level (WW/WL) of 500/50, which 
is a common default setting for abdominal image viewing. For an image displayed on a 10 bit 
monitor 1,024 grayscales are available which equates to approximately 2 gray levels per HU. If it 
is assumed that the human eye can perceive between 64-128 shades of gray, then a change in 
every 4-8 HU would be perceived by the human observer. Referring to Table 17, the 95% CI for 
the spleen and subcutaneous fat indicate that there is likely no clinical significance to these results 
and that from a clinical perspective measurements for the spleen and fat for VUE images are not 
inferior to TUE images.   
 Figure 20 demonstrates differences in the appearance of bone between TUE and VUE 
images. Notice that the spine appears much brighter in the TUE image, which could be a 
consequence of the inability of the material suppression algorithm to accurately distinguish bone 
from an iodine-blood mixture. This has been referred to in the literature as a “subtraction artifact” 
[9]. For this feasibility study, the subtraction of calcium signal in the spine is likely irrelevant for 
assessment of renal masses.  
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Figure 20. Comparison of spine appearance in TUE (left) to VUE (right) 
 
4.1.5 Dose Considerations 
The volume computed tomography dose index (CTDIvol) was recorded from the dose 
report for each patient exam. The average CTDIvol for the pre-contrast phase (TUE) well as for 
the total CT exam are given in Table 18. Note that the reduction (%) is representative of the 
particular exam protocol used for patients in the retrospective study, which involves acquisition 
of multiple post contrast images. For renal protocols, which typically involve the acquisition of 
fewer post-contrast images, the reduction in CTDIvol (%) resulting from elimination of the pre-
contrast phase would be a larger fraction of the total.   
Mean 
Values 
Total 
Number (N) 
Age 
(years) 
Weight 
(kg) 
BSA 
(m2) 
CTDIvol for 
TUE (mGy) 
Total CTDIvol 
(mGy) 
Reduction 
(%) 
Women 27 62.3 70.8 1.96 11.0 113.8 9.7 
Men 33 62.0 67.9 1.94 10.8 127.7 8.5 
Overall 60 62.1 74.6 1.90 10.5 121.5 8.7 
Table 18. Estimated doses from the pre-contrast images for patient exams  
4.1.6 Limitations of the retrospective study 
 The raw CT data for the patient exams used in this study were no longer available; 
therefore the TUE and VUE images could not be reconstructed using identical techniques. The 
TUE images were reconstructed with 60% ASIR and the SOFT reconstruction filter, whereas the 
DECT data used to reconstruct VUE images were reconstructed with 0% ASIR and the 
STANDARD reconstruction filter.  
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4.2 Specific Aim 2 
4.2.1 Technical Notes 
4.2.1.1 Results and discussion: Iodine concentration determination 
 CT numbers were measured for each Optiray-water mixture and plotted to determine a 
relationship between CT number and iodine concentration. The results were plotted and linear 
regression was used to estimate a relationship between CT number and iodine concentration, as 
shown in Figure 21. The CT numbers predicted from previous experiments [38] are plotted 
alongside the CT numbers measured in this experiment. The relationship between CT number and 
iodine concentration was determined to be: 
𝐼𝑜𝑑𝑖𝑛𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (
𝑚𝑔
𝑚𝐿⁄ ) = 0.0501 ∗ (𝐶𝑇 𝑛𝑢𝑚𝑏𝑒𝑟) − 1.08      𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 4.2.1.1 − 1 
 
Figure 21. Correlation between iodine concentration (mg/mL) and CT number (HU) 
 The variation between predicted CT number from previous experimentation and the 
measured data is likely reflective of the variation between energy spectra from CT scanner to CT 
scanner.  
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4.2.1.2 Results and discussion: Phantom set-up verification 
VUE images were reconstructed from DECT imaging of the Jaszczak phantom. The 
results of the experiment for the 31.8 mm diameter sphere (sphere 1) are plotted in Figure 22, and 
Figure 23 for the 25.4 mm sphere (sphere 2).  The results of the Jaszczak phantom study indicate 
that the output of the MSI algorithm for VUE image reconstruction is substantially the same in 
both in positive and negative contrast backgrounds. Encouraged by these results, we proceeded 
with Sub Aim 2.2 of the phantom study. 
 
Figure 22. Positive versus negative contrast comparison for Sphere 1 
 
Figure 23. Positive versus negative contrast comparison for Sphere 2 
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4.2.2 Results: Sub Aim 2.2 
 The measured CT number and noise for each preset imaged with the medium phantom 
can be seen in Figures 24 and 25, respectively. Four GSI protocols were selected for imaging the 
small and medium phantom sizes, and four protocols were selected for imaging the large 
phantom. 
 
Figure 24. VUE CT number measurements for each GSI protocol 
 
Figure 25. VUE image noise measurements for each GSI protocol 
The protocols selected for use in Sub Aim 2.2 are listed in Table 19. GSI preset 10 was 
selected for imaging all three phantoms to bridge the gap between clinical practices and the 
retrospective study for further investigation of other presets in the phantom study. Preset 10 was 
used in image acquisition of almost all patient cases in the retrospective study independent of 
patient size.  
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GSI 
Preset 
Bowtie 
Beam 
Width 
(mm) 
Rotation 
Time (s) 
mA 
CTDIvol 
(pitch 
0.969) 
Used for 
small and 
medium 
phantoms 
10 Large 40 0.8 600 25.5 
11 Medium 40 0.8 600 26.7 
16 Medium 40 0.6 640 22.9 
29 Medium 20 0.8 550 27.6 
Used for 
large 
phantom 
36 Large 40 0.8 360 10.3 
10 Large 40 0.8 600 25.5 
12 Large 20 0.8 600 28.2 
22 Large 40 0.7 375 10.8 
Table 19. Selected GSI presets 
 
4.2.3 Discussion: Sub Aim 2.2 
 It was difficult to assess the accuracy of VUE image CT numbers compared to the TUE 
image baseline, which was acquired with water in the phantom inserts. Recall that the MSI 
algorithm used to reconstruct VUE images subtracts the iodine concentration contained within 
each voxel and replaces it with an equivalent volume of blood [27]. As a result, the TUE images 
acquired with water in the spheres will not be representative of what is expected from the VUE 
images, which would in theory be a blood-water mixture after the iodine replacement. The TUE 
images used in the experiment with water filled spheres provided a baseline measurement of 
approximately 0 HU, whereas the VUE images resulted in an average measurement of 13 HU for 
the 3 cm sphere. 
 An experiment was conducted in an attempt to estimate the expected baseline VUE 
measurement that could be used for comparison of GSI protocols. Mixtures of water and iodine 
were prepared with increasing iodine concentrations, and CT numbers were measured in the 
resulting VUE images. CT number (HU) was plotted against iodine concentration (mg/mL) and 
 54 
 
the relationship was extrapolated to zero to estimate what the expected CT number would be for 0 
mg/mL iodine concentration, which resulted in an expected baseline VUE measurement of 14.7 
HU. The prominent issue with this method was that a GSI protocol had to be selected in order to 
acquire DECT datasets for VUE image reconstruction; therefore, the results are inherently biased 
toward that protocol. Since the goal of this Sub Aim is to select the top candidate protocols, this is 
problematic. As a result, four GSI candidate protocols were selected by careful evaluation of the 
full protocols list, taking into consideration measured image noise and the specific technique 
parameters.  
 The GSI protocols were selected to allow for variation in CT acquisition parameters 
between protocols, as well as with consideration to the amount of noise measured from each.  
For the medium and small phantoms (refer to Table 19): 
• GSI 10 selected because of common clinical use 
• GSI 10 → GSI 11 variation in bowtie filter 
• GSI 11 → GSI 16 variation in rotation time and mA 
• GSI 16 → GSI 29 variation in beam width 
 
For the large phantom (refer to Table 19):  
• GSI 10 selected because of common clinical use 
• GSI 36 → GSI 10 variation in mA, mAs, and CTDIvol 
• GSI 10 → GSI 12 variation in beam width 
• GSI 12 → GSI 22 variation in rotation time and mA 
Example images acquired using each selected preset at the same location in the small phantom 
with 5.00 mm thickness are shown in Figure 26, and example images of each preset selected for 
the large phantom are shown in Figure 27.  
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Figure 26. Example images of the medium phantom for the selected GSI presets (from left 
to right) GSI 10, 11, 16, and 29 
     
Figure 27. Example images of the large phantom for the selected GSI presets (from left to 
right) GSI 10, 12, 22, and 36 
 
Limitations of Sub Aim 2.2 
In order to make a more accurate comparison of the performance of each GSI protocol in 
relation to the expected TUE measurement, the experiment would need to be conducted with 
blood only for TUE image acquisition, and a blood-iodine mixture for DECT image acquisition. 
This would allow for reconstruction of VUE images expected to have CT number similar to the 
TUE images, considering the nature of the MSI algorithm. Using blood would allow for an 
assessment of the variation of CT numbers for all GSI protocols to TUE image CT numbers.  
 
 
 
 
 
 56 
 
4.2.4 Results: Sub Aim 2.3 
  A Bayesian Hierarchical model was used to analyze all phantom data. This method was 
chosen because. This model was chosen to allow for direct quantification of uncertainty resulting 
from many parameters in the study, including variation in lesion size, patient size, enhancement, 
etc. Note that the error bars for each graph in the subsequent sections represent ± σtotal (equation 
3.2.4-2). Additional graphs for each section can be found in Appendix 6.6.  
Scenario 1 
 Each phantom was imaged in varying configurations for a baseline CT number of     
-100 HU, simulated with vegetable oil in the inserts. Because there was no enhancement for this 
scenario, a direct comparison was made for VUE vs. TUE CT number measurements. Graphs of 
varying parameters can be seen in Figures 28 and in Appendix 6.6. The results of the Bayesian 
Hierarchical model for comparison of VUE techniques to TUE images are quantitatively 
summarized in Table 20 in the following section.  
 
Figure 28. Evaluation of the impact of GSI protocol on CT number in VUE vs. TUE images. 
Plotted data represent the 1 cm sphere in the center of the FOV. 
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Scenario 2 
 Each phantom was imaged in varying configurations for a baseline CT number of     
0 HU, simulated with distilled water in the inserts. Because there was no enhancement for this 
scenario, a direct comparison was made for VUE vs. TUE CT number measurements.   
 
Figure 29. Comparison of each GSI preset to TUE CT number measurements for the 1 cm 
lesion size located in the center of the SFOV. 
 For scenarios 1 and 2, the TUE and VUE CT number measurements were directly 
compared, because there was no enhancement in post-contrast images. As a result, a single model 
was used for statistical analysis of these scenarios. Table 20 quantitatively represents the results 
of each GSI protocol as compared to the TUE image measurements. Note that the results are 
given as the difference between each VUE protocol as compared to the TUE measurements, 
taking into account uncertainties from each variable. The posterior probability can be interpreted 
as: 
 Posterior probability > 0.95 implies significant positive variation of VUE images 
 Posterior probability < 0.05 implies significant negative variation of VUE images 
 Posterior probability = 0.5 implies no significant difference between VUE and TUE 
images 
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The results from the Bayesian Hierarchical model, shown in Table 20, indicate that there 
is no statistically significant variation between each VUE protocol and the TUE images across a 
wide range of varying parameters (including lesion size and position of the lesion within the field 
of view) for simulated angiomyolipoma and benign cystic lesions. The parameter σProtocol given in 
Table 20 represents the standard deviation in CT number measurements resulting from 
differences in GSI protocol, as computed by the Bayesian Hierarchical model.  
 
Small Phantom Medium Phantom Large Phantom 
95% CI for 
difference 
Posterior 
Probability 
95% CI for 
difference 
Posterior 
Probability 
95% CI for 
difference 
Posterior 
Probability 
VUE-10 [10] (-1.437, 2.380) 0.564 (-2.111, 1.838) 0.502 (-10.246, 1.006) 0.238 
VUE-11 [12] (-1.297, 2.434) 0.555 (-1.786, 2.239) 0.515 (-9.990, 1.026) 0.25 
VUE-16 [22] (-1.441, 2.704) 0.56 (-1.252, 2.973) 0.56 (-11.138, 0.916) 0.226 
VUE-29 [36] (-1.595, 2.148) 0.524 (-1.584, 2.360) 0.531 (-8.871, 1.353) 0.273 
σProtocol (0.029, 2.388) -- (0.029, 2.582) -- (0.037, 7.302) -- 
Table 20. Bayesian Hierarchical Model results for scenarios 1 and 2. The presets in brackets 
are those used for the large phantom.   
Scenario 3  
 For Scenarios 3-5, the enhancement values of interest will be labeled as follows in each 
of the graphs: 
𝑽𝑼𝑬 𝒊𝒎𝒂𝒈𝒆 𝒃𝒂𝒔𝒆𝒅 𝒆𝒏𝒉𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕: ∆𝑉𝑈𝐸 = 𝐷𝐸𝐶𝑇𝑝𝑜𝑠𝑡−𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 − 𝑉𝑈𝐸 
𝑻𝑼𝑬 𝒊𝒎𝒂𝒈𝒆 𝒃𝒂𝒔𝒆𝒅 𝒆𝒏𝒉𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕: ∆𝑇𝑈𝐸 = 𝑆𝐸𝐶𝑇𝑝𝑜𝑠𝑡−𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 − 𝑇𝑈𝐸 
The error bars in graphs shown in Scenarios 3-5 represent ± σtotal (as described in section 3.2.4), 
where the term for standard deviation within each ROI measurement (σN) was added in 
quadrature for pre- and post-contrast measurements to estimate the error for enhancement.  
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 Each phantom was imaged in varying configurations for a baseline CT number of     
20 HU, simulated with an apple juice and distilled water mixture in the inserts. For this scenario 
two cases were simulated to mimic low and intermediate enhancement. Recall that one solution 
was made and used for all variation in phantom configuration, including phantom size. As can be 
seen in Figure 30, the same solution measured different CT numbers across patient size. This 
variation in measured enhancement across patient size is not problematic because the same 
solution was used to acquire SECT and DECT post-contrast images for each phantom, which is 
the comparison of interest for this study.  
 
Figure 30. Scenario 3: Comparison of enhancement with TUE vs. VUE as the baseline 
image for varying patient size, enhancement, and GSI presets for the 3 cm sphere located in 
the periphery of the SFOV 
Scenario 3 was unique from all other scenarios because a baseline value of 20 HU was simulated. 
As a result, an individual Bayesian Hierarchical model was used to fit the data for this scenario to 
most effectively quantify the uncertainties and determine the posterior probability. The results are 
given as the difference between enhancement values for each GSI protocol as the baseline image 
compared to measurements with TUE images as the baseline, taking into account uncertainty 
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resulting from each parameter. As previously stated the posterior probability can be interpreted 
as: 
 Posterior probability > 0.95 implies significant positive variation of VUE images 
 Posterior probability < 0.05 implies significant negative variation of VUE images 
 Posterior probability = 0.5 implies no significant difference between VUE and TUE 
images 
The results from the Bayesian Hierarchical model, shown in Table 21, indicate that there are 
significant differences between each enhancement from each VUE protocol and the TUE images 
across a wide range of varying parameters (including lesion size and position of the lesion within 
the field of view) for simulation of Bosniak category II-IIF lesions. The 95% credible interval is 
representative of the difference in enhancement values from each GSI protocol to the TUE 
images, which is significant. This is also demonstrated visually in Figure 30.  
  
Small Phantom Medium Phantom Large Phantom 
95% CI for 
difference 
Posterior 
probability 
95% CI for 
difference 
Posterior 
probability 
95% CI for 
difference 
Posterior 
probability 
VUE-10 [10] (-18.312, -14.531) 0 (-15.565, -12.176) 0 (-10.263, -4.618) 0 
VUE-11 [12] (-18.339, -14.574) 0 (-15.948, -12.570) 0 (-9.650, -3.942) 0 
VUE-16 [22] (-18.458, -14.613) 0 (-15.783, -12.370) 0 (-11.324, -5.851) 0 
VUE-29 [36] (-18.106, -14.423) 0 (-16.008, -12.634) 0 (-10.238, -4.622) 0 
σProtocol (4.359, 21.15) -- (3.759, 18.258) -- (1.954, 10.482) -- 
Table 21. Bayesian Hierarchical Model results for scenario 3. The presets in brackets are 
those used for the large phantom.   
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Simulation 4 
 Each phantom was imaged under varying configurations for a baseline CT number of     
40 HU simulated with an apple juice and distilled water mixture in the inserts. For this scenario 
low enhancement (5-10 HU) and intermediate (15- 20 HU) enhancement cases were simulated. 
Graphs of different parameters can be seen in Figure 31 and in Appendix 6.6.  
 
Figure 31. Scenario 4: Comparison of enhancement with TUE vs. VUE as the baseline 
image for varying patient size, iodine concentrations, and GSI presets for the 3 cm sphere 
located in the periphery of the SFOV  
 Scenarios 4 and 5 simulated as baseline lesion measuring 40 HU, and then varying 
enhancement situations were simulated. Consequently, a separate Bayesian Hierarchical model 
was used to fit this data, and is shown in Table 22.  
 
 
 
 
-4
-2
0
2
4
6
8
10
12
14
16
18
∆
TU
E
∆
V
U
E(
1
0
)
∆
V
U
E(
1
1
)
∆
V
U
E(
1
6
)
∆
V
U
E(
2
9
)
∆
TU
E
∆
V
U
E(
1
0
)
∆
V
U
E(
1
1
)
∆
V
U
E(
1
6
)
∆
V
U
E(
2
9
)
∆
TU
E
∆
V
U
E(
1
0
)
∆
V
U
E(
1
2
)
∆
V
U
E(
2
2
)
∆
V
U
E(
3
6
)
Small Medium Large
En
h
an
ce
m
e
n
t 
(H
U
)
Variation in GSI protocol and enhancement
Low enhancement 
Intermediate 
enhancement 
 62 
 
Scenario 5 
 Each phantom was imaged under varying configurations for a baseline CT number of 40 
HU simulated with an apple juice and distilled water mixture in the inserts. For this scenario only 
high enhancement (40 HU) was simulated to mimic a Bosniak category IV lesion that is clearly 
malignant. Figure 32 shows a comparison of enhancement measurements with each GSI protocol 
used as the baseline for calculation compared to TUE baseline measurements.  
 
Figure 32. Scenario 5: Comparison of enhancement with TUE vs. VUE as the baseline 
image for varying patient size and GSI presets for the 3 cm sphere located in the periphery 
of the SFOV 
The results from the Bayesian Hierarchical model, shown in Table 22, indicate that there are 
significant differences between enhancement measurements for each baseline VUE image and the 
TUE images across a wide range of varying parameters (including lesion size and position of the 
lesion within the field of view). The 95% credible interval is representative of the difference in 
enhancement values from each GSI protocol to the TUE images, for which significance is 
demonstrated by a posterior probability of 0 for all protocols across all phantom sizes. This is also 
demonstrated visually in Figure 31. The parameter σProtocol is the variation between enhancement 
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for all VUE and TUE image based measurements, as calculated from the Bayesian Hierarchical 
model.  
 
Small Phantom Medium Phantom Large Phantom 
95% CI for 
difference 
Posterior 
probability 
95% CI for 
difference 
Posterior 
probability 
95% CI for 
difference 
Posterior 
probability 
VUE-10 [10] (-10.469, -5.940) 0 (-12.028, -5.740) 0 (-13.234, -6.247) 0 
VUE-11 [12] (-12.113, -7.324) 0 (-13.123, -6.705) 0 (-11.166, -4.593) 0 
VUE-16 [22] (-11.791, -7.013) 0 (-12.918, -6.201) 0 (-14.340, -7.332) 0 
VUE-29 [36] (-11.417, -6.491) 0 (-12.168, -5.508) 0 (-11.608, -5.021) 0 
σProtocol (2.386, 12.267) -- (2.402, 12.672) -- (2.384, 12.862) -- 
Table 22. Bayesian Hierarchical Model results for scenario 3. The presets in brackets are 
those used for the large phantom.   
 Position of the simulated lesion within the field of view was varied between the center 
and periphery locations of the phantom, as shown in Figure 7. The standard deviation resulting 
from position of the lesion within the FOV was estimated using probabilities from the Bayesian 
Hierarchical model. The deviation, σFOV, is shown in Table 23. The posterior probabilities 
calculated from the Bayesian Hierarchical model indicate significant differences in CT number 
(scenarios I and II) and enhancement (scenarios III-V) measurements resulting from different 
locations within the FOV in VUE enhancement measurements for all scenarios. Previous studies 
have also found that the material decomposition function of GSI using a GE CT750 HD scanner 
is dependent on position within the FOV for varying iodine concentrations, and may be 
attributable to beam hardening in FOV locations where CT number uncertainty was high [44].   
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Scenario 
  
Small Phantom Medium Phantom  Large Phantom 
95% CI for 
variation (σFOV) Ext Val 
95% CI for 
variation Ext Val 
95% CI for 
variation (σFOV)  Ext Val 
I - II 
(0.055, 8.099) 1 (0.031, 2.587) 1 (0.063, 8.139) 1 
III 
(0.074, 1.994) 1 (0.061, 1.793) 1 (0.033, 2.437) 1 
IV - V 
(0.031, 2.170) 1 (0.033, 3.343) 1 (0.070, 3.928) 1 
Table 23. Variation in FOV for each Scenario (σFOV) 
 Change in lesion size was considered as a variable by imaging lesions 1 cm, 2 cm, and 3 
cm in diameter for each patient size, as shown in Figure 6. The standard deviation resulting from 
lesion size for each scenario, σLESION, was calculated in the Bayesian Hierarchical model and is 
shown in Table 24. 
Scenario 
Lesion 
size 
Small Phantom Medium Phantom  Large Phantom 
95% CI for 
variation (σLESION) 
Posterior 
probability  
95% CI for 
variation (σLESION) 
Posterior 
probability 
95% CI for 
variation (σLESION) 
Posterior 
probability 
III 
 1 cm (-2.125, 0.857) 0.197 (-2.301, 0.773) 0.154 (-5.191, 0.824) 0.074 
 2 cm -- -- -- -- -- -- 
 3 cm (-0.391, 2.477) 0.928 (-0.726, 2.099) 0.849 (-2.489, 3.120) 0.587 
IV - V 
 1 cm (-4.0766, 1.0409) 0.127 (-6.758, 0.024) 0.026 (-4.903, 1.393) 0.138 
 2 cm -- -- -- -- -- -- 
 3 cm (-0.667, 4.237) 0.922 (-0.986, 5.909) 0.921 (-1.558, 4.157) 0.828 
Table 24. Variation resulting from lesion size for scenarios where enhancement was 
simulated (σLESION) 
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 The standard deviation attributed to changing lesion size, σLESION, was computed for the 1 
cm and 3 cm lesions relative to the deviation of each from measurements in the 2 cm sphere. 
Significant differences between VUE and TUE enhancement measurements (posterior probability 
> 0.95 or posterior probability < 0.05) for the 1 cm sphere could be a result of partial volume 
averaging because the image thickness used throughout the study was 5 mm. Notice that the most 
change due to lesion size was observed in scenarios I and II, and could be attributable to the large 
differences in baselines values (-100 for scenario I and 0 for scenario II) considered in the model. 
4.2.5 Discussion: Sub Aim 2.3 
 For discussion of the results of the phantom study, the enhancement values of interest 
will be labeled as follows: 
𝑽𝑼𝑬  𝒊𝒎𝒂𝒈𝒆 𝒃𝒂𝒔𝒆𝒅 𝒆𝒏𝒉𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕: ∆𝑉𝑈𝐸 = 𝐷𝐸𝐶𝑇𝑝𝑜𝑠𝑡−𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 − 𝑉𝑈𝐸 
𝑻𝑼𝑬 𝒊𝒎𝒂𝒈𝒆 𝒃𝒂𝒔𝒆𝒅 𝒆𝒏𝒉𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕: ∆𝑇𝑈𝐸 = 𝑆𝐸𝐶𝑇𝑝𝑜𝑠𝑡−𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 − 𝑇𝑈𝐸 
 It has been stated that the determination of enhancement is the most important criterion 
used to distinguish surgical from nonsurgical renal masses [17]. Based on the calculated 
difference between pre- and post-contrast images, a lesion is placed into one of the following 
categories [17]: 
• Unenhancing: difference is < 10  
• Indeterminate (and needs further evaluation): difference is between 10 -20 HU 
• Enhancing: difference is > 20 HU 
In light of this it is clear that accurate quantification of enhancement is crucial for borderline 
lesions, in the range of approximately 5-25 HU (when considering systematic and random error), 
for appropriate diagnosis of renal lesions. Considering the results of Scenarios 3 and 4 in the 
phantom study, it is clear that VUE as the baseline image for enhancement measurement is not a 
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suitable replacement for TUE images. As demonstrated in Figures 30-31 there were cases in 
which VUE-based enhancement measurements would have led to different categorization of the 
simulated lesions than TUE-based enhancement measurements. Because enhancement was 
always lower for VUE-based measurements, this led to categorization of “unenhancing” in many 
cases where the TUE-based measurements would have led to categorization of an “enhancing” or 
“indeterminate” lesion (requiring surgical resection or further evaluation). The clinical 
implications of these differences in enhancement values could be severe and lead to false negative 
diagnosis of renal lesions. Table 25 quantifies the number of times that VUE-based enhancement 
measurements lead to different categorization than TUE-based measurements for Scenarios III-V. 
As previously stated, the categories were considered to be unenhancing (HU < 10), intermediate 
(10 < HU > 20), or enhancing (HU > 20).   
 Total Scenario III Scenarios IV-V 
Number of samples 650 288 362 
Number of times 
categorization did not match 
373 229 144 
Number of times 
categorization did match 
277 59 218 
Accuracy (%) 42.6% 20.5% 60.2% 
Table 25. Comparison of categorization of TUE and VUE measurements to evaluate clinical 
relevance of the results 
 The percentage of matching categorization is higher for Scenarios IV-V because this 
includes data from Scenario V, which simulated a highly enhancing renal lesion (approximately 
40 HU enhancement). Although differences between enhancement measurements were significant 
in Scenario V, they rarely led to differences in categorization of the lesion as enhancing or non-
enhancing. For example, a difference of 10 HU in enhancement between TUE- and VUE-based 
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data for a borderline lesion enhancing 20 HU is more clinically meaningful than the same 
difference for a lesion that enhances a total of 50 HU. This experiment has demonstrated that for 
highly enhancing renal lesions, enhancement calculations for TUE and VUE images would lead 
to the same categorization of the lesion, and therefore confirm that VUE images would be a 
feasible replacement to TUE images in these cases. However, the results of scenario III-IV 
indicate that enhancement differences between VUE-based compared to TUE-based 
measurements are too significant; therefore the results of this study indicate that it is not feasible 
to replace TUE with VUE images in lesions which contain low concentrations of iodine in post-
contrast imaging. Recall that multiphase renal CT exams are performed to characterize and 
diagnose renal lesions, the nature of which is not known prior to examination. As a result, VUE 
images are not a suitable replacement for TUE images for determination of enhancement because 
the feasibility could not be demonstrated in the cases of all lesion types studied in these 
experiments.  
 The presets that returned results that matched most closely to TUE based enhancement 
measurements were determined for each scenario by the Bayesian Hierarchical model, which 
quantified and accounted for sources in uncertainty resulting from the many parameters in the 
experiment. A summary of these results for all scenarios can be found in Table 30 in Appendix 
6.6. For the small phantom GSI-29 most closely matched TUE measurements and for the medium 
phantom GSI-10 most closely matched. For the large phantom the protocol most closely matching 
TUE measurements varied for each scenario.   
 A note should also be made regarding the subtraction artifact, which was also observed in 
the retrospective study and discussed in section 4.1.4. A delrin rod with a CT number of 
approximately 300 HU was included in the phantom design to simulate spine. A subset of images 
was randomly selected for ROI measurements in the spinal region, the dimensions of which are 
given in Table 7. Figure 33 shows a comparison of each GSI preset to the TUE CT number 
measurement.  
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Figure 33. Comparison of VUE to TUE CT numbers measured in the delrin rod, which 
simulated bone. 
 For all measurements, the CT number measured in the VUE images was less than that 
measured in the TUE image. This further confirms the presence of the subtraction artifact in 
images reconstructed using the MSI algorithm. This is explained by the representation of all 
materials within each voxel as a weighted combination of water and iodine. As demonstrated in 
Figure 1 (section 1.3), the algorithm interprets bone as a weighted combination of water and 
iodine, and therefore removes the calculated fraction of iodine present resulting in removal of 
calcium signal in the reconstructed VUE image. 
  Measurements of the phantom background were recorded in a subset of images to 
compare the CT number in TUE to VUE images. As shown in Figure 34, the average 
measurements made in the phantom background are similar for TUE and VUE images, which is 
expected because these high density polyethylene regions did not contain iodine contrast.   
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Figure 34. Comparison of each GSI preset to the average TUE CT number measured in the 
background of the phantom 
Limitations of this study: 
 The MSI algorithm has been stated to replace the estimated volume of iodine with an 
equivalent volume of blood [27]. In light of this, use of blood for TUE baseline image 
acquisition, and then use of blood and Optiray mixtures would have been the most preferable 
experimental approach. However, due to limitations regarding the accessibility of blood, a 
surrogate material was used in instead of blood. The surrogate material selected was apple juice, 
due to the similarities in attenuation measurements and effective atomic numbers. The use of this 
surrogate in place of blood could have affected the results, and therefore this limitation should be 
considered with the results.  
The phantom background is HDPE (approximately -65 HU), which has a spectral curve 
which varies from that of soft tissue, which potentially affected DECT measurements. The 
Jaszscak phantom study verified that this variation is minimally significant for VUE CT number 
measurements (Figures 22-23), but it was signification for DECT measurements. Consequently, 
the use of HDPE as the background material could have affected DECT post-contrast 
measurements, which would have in turn affected enhancement measurements.  
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 Previous studies have sought to identify the optimal monochromatic keV to match 120 
kVp SECT images [45]. Some preliminary results have indicated that this value may be 68 keV 
instead of the commonly used 70 keV. Using 70 keV for comparison to 120 kVp SECT images 
therefore may not be the most accurate comparison, which could affect the post-contrast 
measurements and consequently overall enhancement. This was assessed by measuring CT 
numbers for varying monochromatic energies to estimate the potential difference that could result 
if the 70 keV used in these experiments is not the optimal monochromatic energy for post-
contrast images. An example of the difference for Scenarios III (intermediate enhancement) and 
IV (low enhancement) is shown in Table 26. The difference between the potentially more suitable 
68 keV and the currently used 70 keV is approximately 1 HU for each case considered. Referring 
to Figures 30-31 (visually) and Tables 21-22 (quantitatively), the difference in enhancement is 
larger than 1 HU, confirming that the most considerable difference originates from VUE image 
measurements, and not from the selection of monochromatic energy for DECT post-contrast 
measurements. Selection of keV to represent 120 kVp images did not affect the results of the 
experiment.  
keV 
CT number 
Scenario III low 
enhancement (HU) 
SD 
CT number Scenario 
IV intermediate 
enhancement (HU) 
SD 
65 39.6 2.9 54.9 3.0 
68 37.1 3.0 53.1 3.1 
69 36.4 3.1 52.5 3.2 
70 35.9 3.1 52.0 3.2 
71 35.4 3.1 51.7 3.3 
72 34.5 3.2 51.0 3.4 
75 33.1 3.3 49.8 3.5 
Table 26. Assessment of the effect of variation in monochromatic energy selection (keV) on 
CT number for the small phantom using GSI protocol 29 
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4.3 Specific Aim 3 
4.3.1 Results 
 Preliminary data for evaluation of the effect of ASIR level on CT number accuracy were 
collected in Sub Aim 2.2. The purpose for collecting this data was to compare the TUE method 
(60% ASIR with a soft filter) to the VUE method (0% ASIR with a standard filter) of image 
reconstruction in the retrospective study to determine which method to use in Sub Aim 2.3. The 
results of this study are shown in Table 27 and Figure 35. 
 0% ASIR Standard filter 60% ASIR Soft filter 
% Difference 
between mean 
CT numbers ROI Section 
Mean CT 
Number 
Mean 
Noise 
Mean CT 
Number 
Mean 
Noise 
3 cm sphere insert 13.33 6.17 13.03 6.14 0.23 
1 cm sphere insert 21.94 7.76 22.08 7.69 0.64 
Spine (Delrin rod) 311.34 5.80 311.48 5.53 0.05 
Phantom 
background 
-64.75 6.41 -64.66 5.79 0.14 
Table 27. Comparison of retrospective study image reconstruction techniques 
 
Figure 35. Comparison of retrospective study image reconstruction techniques 
 For Specific Aim 3, three levels of ASIR 0%, 60%, and 100% were chosen to assess the 
effect of ASIR level on enhancement values. Subsets of experiments from Specific Aim 2.3 were 
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chosen for reconstruction with the stated levels of ASIR. The results were fitted and analyzed 
using a Bayesian Hierarchical model, the results of which are given in Table 28. The mean of the 
slopes of ASIR level in relation to CT number for each phantom configuration is given as µASIR, 
and the associated standard deviation, is given by σASIR. A slope approaching zero implies no 
difference in CT number for changing ASIR level. The absolute value of the slope indicates the 
most anticipated difference in CT number resulting from maximum possible difference in ASIR 
level. For example a slope of -0.0168 implies that the maximum possible difference would be 
1.68 HU.   
  Mean SD 95% Confidence Interval 
Small 
Patient 
µASIR -0.0168 0.0042 (-0.0252, -0.0084) 
σASIR 0.0161 0.003 (0.0113, 0.023) 
Medium 
Patient 
µASIR -0.0174 0.0053 (-0.0278, -0.007) 
σASIR 0.0201 0.0039 (0.0137, 0.029) 
Large 
Patient 
µASIR -0.0258 0.0068 (-0.0394, -0.0126) 
σASIR 0.0252 0.0053 (0.0166, 0.0372) 
Table 28. Specific Aim 3 results 
 
4.3.2 Discussion 
 Results of Sub Aim 3 indicate that there is no clinical significance resulting from 
changing the level of ASIR applied to the reconstructed image on measured CT number. The 
largest mean slope was -0.0258 for the large patient, which corresponds to a maximum 
anticipated difference in CT number of 2.58 HU for any range of variation in ASIR level applied. 
These results confirm the validity of the results from the quantitative retrospective study in 
Specific Aim 1, despite the differences in reconstruction techniques. However, confirmation that 
ASIR level does not quantitatively effect CT number does not validate the results of the 
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qualitative study. ASIR level affects the perceived “graininess” or noise of the image, and 
therefore very likely had an effect on the qualitative scores given by the radiologists for VUE 
images (which had 0% ASIR) as compared to TUE images (which had 60% ASIR).  
   
Figure 36. Visual comparison of variation in ASIR level: 0% (left), 60% (center), 100% 
(right) 
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Chapter 5. Conclusions 
5.1 Specific Aim Conclusions 
 The results of the retrospective study indicate that VUE images have the potential to 
replace TUE images clinically. In the qualitative study VUE images were found to be inferior to 
TUE images for visualization of major vessels and depiction of liver parenchyma, which may be 
attributed in part to the variation in reconstruction techniques. In the quantitative study VUE 
images were found to be non-inferior to TUE images only in the liver, medulla, and cystic lesions 
based on a paired t-test. However, after consideration of the clinical relevance of the results, VUE 
images were determined to be non-inferior for the spleen and subcutaneous fat as well. An 
important artifact observed in this study, referred to as the subtraction artifact, also affects the 
feasibility of replacing TUE with VUE images because of the importance of the visibility of 
calcifications in renal lesion characterization.  
A phantom study was conducted to assess VUE images across a wide range of clinical 
scenarios. The results indicate that enhancement values for VUE based measurements are not 
significantly different from TUE based measurements for simulated AML lesions and benign 
cystic lesions. However, the results for simulation of Bosniak category II-IV lesions indicated 
that enhancement values are significantly different when using VUE as the baseline for 
enhancement measurements. These results indicate that for borderline enhancing lesions VUE 
images are not a suitable replacement for TUE images. Considering the purpose of diagnostic 
renal CT, in which the lesion type is not known prior to imaging, VUE images are currently not 
suitable for diagnosis of an unknown renal lesion type. Although the VUE images reconstructed 
using the MSI algorithm in its current form likely cannot be used as a replacement for TUE 
images, we believe the results of this study still prove the potential for this application.  
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The impact of ASIR level on VUE enhancement accuracy was assessed in Specific Aim 
3. The results from the mixed effects model indicate that the level of ASIR applied does not affect 
measured CT numbers or enhancement. These results further validate the results of the quantitate 
study in Specific Aim 1, despite the difference in reconstruction techniques between TUE and 
VUE images.   
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5.2 Future Work 
 Repeating a qualitative retrospective study with radiologists (Sub Aim 1.1) where the 
reconstruction techniques between TUE and VUE images are identical would be valuable. 
Preferably, these cases would involve more renal disease, since most cases used in this 
retrospective analysis were patients with pancreatic indication and no associated renal lesions. 
Additionally, a subset of images would be selected randomly for separate qualitative evaluation 
of visualization of calcifications. For this study, TUE and VUE images would be shown side by 
side, and the radiologists would compare intensity and number of calcifications visible in each 
image.  
 Selecting a subset of experiments from Sub Aim 2.3, such as scenarios III-IV for repeated 
analysis with blood used would allow for more direct evaluation of the clinical performance of 
the algorithm.  
 
 
 
 
 
 
 77 
 
6. Appendix 
6.1 Qualitative Questionnaire 
Instructions: An image will be presented to you, which you can window/level to your preference. 
Please choose one answer for each of the following questions to reflect your opinions as 
accurately as possible for each image given.  
Number of years of experience reading CT abdominal exams: _________ 
Survey 
1. Visualization of major vessels (considering hepatic, portal, and renal veins in particular) 
1. Very poor 
2. Poor 
3. Adequate 
4. Good 
5. Very good 
2. Visually sharp reproduction of the pancreatic contour 
1. Very poor 
2. Poor 
3. Adequate 
4. Good 
5. Very good 
3. Visualization of calcifications 
1. Very poor 
2. Poor 
3. Adequate 
4. Good 
5. Very good 
4. Depiction of liver parenchyma, e.g., ability to determination of the degree of fatty 
infiltration  
1. Very poor 
2. Poor 
3. Adequate 
4. Good 
5. Very good 
5. Visualization of adrenal glands 
1. Very poor 
2. Poor 
3. Adequate 
4. Good 
5. Very good 
6. Corticomedullary differentiation 
1. No differentiation  
2. Slight differentiation 
3. Extreme differentiation  
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6.2 Designs for each phantom 
Small Phantom Design 
 
Medium Phantom Design 
 
Large Phantom Design 
 
 79 
 
6.3 Complete List of GSI Protocols used in Sub Aim 2.2. 
GSI 
Preset SFOV 
Rot time 
(s) 
Beam width 
(mm) mA 
CTDIw 
(mGy) 
CTDIvol 
0.531 pitch 
CTDIvol 
0.984 pitch 
1 Large 0.5 40 630 17.49 32.94 17.77 
51 Large 0.5 40 260 10.18 19.17 10.35 
54 Large 0.6 40 275 8.96 16.87 9.11 
15 Large 0.6 40 640 21.5 40.49 21.85 
31 Large 0.6 40 375 12.72 23.95 12.93 
40 Large 0.6 40 360 12.09 22.77 12.29 
22 Large 0.7 40 375 14.79 27.85 15.03 
44 Large 0.7 40 275 10.51 19.79 10.68 
48 Large 0.7 40 260 8.91 16.78 9.05 
10 Large 0.8 40 600 25.13 47.33 25.54 
27 Large 0.8 40 550 23.19 43.67 23.57 
36 Large 0.8 40 360 10.14 19.10 10.30 
4 Large 0.9 40 600 28.47 53.62 28.93 
5 Large 1.0 40 600 32.01 60.28 32.53 
17 Large 0.6 20 640 23.41 44.09 23.79 
33 Large 0.6 20 375 13.69 25.78 13.91 
24 Large 0.7 20 375 15.87 29.89 16.13 
12 Large 0.8 20 600 27.33 51.47 27.77 
7 Large 1.0 20 600 34.87 65.67 35.44 
3 Medium 0.5 40 630 18.33 34.52 18.63 
52 Medium 0.5 40 360 10.59 19.94 10.76 
16 Medium 0.6 40 640 22.46 42.30 22.83 
32 Medium 0.6 40 375 13.61 25.63 13.83 
41 Medium 0.6 40 360 12.86 24.22 13.07 
55 Medium 0.6 40 375 9.51 17.91 9.66 
23 Medium 0.7 40 375 15.56 29.30 15.81 
45 Medium 0.7 40 375 11.1 20.90 11.28 
49 Medium 0.7 40 260 9.54 17.97 9.70 
11 Medium 0.8 40 600 26.27 49.47 26.70 
28 Medium 0.8 40 550 24.6 46.33 25.00 
37 Medium 0.8 40 260 10.81 20.36 10.99 
6 Medium 1.0 40 600 33.43 62.96 33.97 
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35 Medium 0.5 20 630 19.85 37.38 20.17 
53 Medium 0.5 20 360 11.51 21.68 11.70 
18 Medium 0.6 20 640 24.42 45.99 24.82 
34 Medium 0.6 20 375 14.16 26.67 14.39 
42 Medium 0.6 20 360 14.07 26.50 14.30 
56 Medium 0.6 20 275 10.34 19.47 10.51 
25 Medium 0.7 20 375 16.76 31.56 17.03 
46 Medium 0.7 20 275 11.99 22.58 12.18 
50 Medium 0.7 20 260 10.24 19.28 10.41 
13 Medium 0.8 20 600 28.58 53.82 29.04 
29 Medium 0.8 20 550 26.74 50.36 27.17 
38 Medium 0.8 20 260 11.69 22.02 11.88 
2 Medium 0.9 20 600 32.32 60.87 32.85 
8 Medium 1.0 20 600 36.34 68.44 36.93 
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6.4 Phantom study image acquisition matrix examples 
Patient 
Size 
Lesion 
Size 
Image 
Patient 
Size 
Lesion 
Size 
Image 
Patient 
Size 
Lesion 
Size 
Image 
Small 1 cm TUE Medium 1 cm TUE Large 1 cm TUE 
  
Post-
contrast 
  
Post-
contrast 
  
Post-
contrast 
 
2 cm TUE  2 cm TUE  2 cm TUE 
  
Post-
contrast 
  
Post-
contrast 
  
Post-
contrast 
 
3 cm TUE  3 cm TUE  3 cm TUE 
  
Post-
contrast 
  
Post-
contrast 
  Post-
contrast 
Table 29. SECT image acquisition checklist for each scenario 
Patient 
Size 
Lesion 
Size 
GSI 
preset 
Patient 
Size 
Lesion 
Size 
Thickness 
(mm) 
GSI 
preset 
Patient 
Size 
Lesion 
Size 
GSI 
preset 
SMALL 1 cm 10 MEDIUM 1 cm 5 10 Large 1 cm 10 
    11       11     12 
    16       16     22 
    29       29     36 
  2 cm 10   2 cm 5 10     10 
    11       11     12 
    16       16     22 
    29       29     36 
   3 cm 10    3 cm 5 10     10 
    11       11     12 
    16       16     22 
    29       29     36 
Table 30. DECT image acquisition checklist for each post-contrast scenario for VUE images 
reconstruction 
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6.5 Sub Aim 1 Results: Intra-observer variability between the radiologists 
 
Figure 37. Intra-observer variability for Radiologist 1 
 
Figure 38. Intra-observer variability for Radiologist 2 
 
Figure 39. Intra-observer variability for Radiologist 3 
0
1
2
3
4
5
A
ve
ra
ge
 S
co
re
Intra-observer variability: Radiologist 1
Repeat 1
Repeat 2
0
1
2
3
4
5
A
ve
ra
ge
 S
co
re
Intra-observer variability: Radiologist 2
Repeat 1
Repeat 2
0
1
2
3
4
5
A
ve
ra
ge
 S
co
re
Intra-observer variability: Radiologist 3
Repeat 1
Repeat 2
 83 
 
6.6 Phantom Study Simulation 1 graphs 
The error bars for each graph represent ± the standard deviation for the results represented by 
each bar in the graph.  
Scenario 1 
 
 
Figure 40. Comparison of TUE vs. VUE enhancement values for variation of position of 
lesion within the FOV for the 1 cm sphere and the specified GSI protocols. 
 
Figure 41. Comparison of TUE vs. VUE enhancement values for variation in phantom and 
lesion sizes for the specified GSI protocols and lesions located in the periphery of the SFOV. 
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Scenario 2 
 
Figure 42. Comparison of TUE vs. VUE enhancement values for variation in phantom size 
for 2 cm lesion and the identified GSI protocols. 
Scenario 3 
 
Figure 43. Comparison of TUE vs. VUE enhancement values for variation of position of 
lesion within the FOV for the 1 cm sphere and the specified GSI. 
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Scenario 4 
 
Figure 44. Comparison of TUE vs. VUE enhancement values for variation in phantom and 
lesion sizes for the GSI protocols specified and lesions located in the periphery of the SFOV. 
Scenario 5 
 
Figure 45. Overall comparison of low, intermediate, and high enhancement scenarios for a 
40 HU baseline for the 3 cm lesions located in the periphery of the SFOV 
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Scenario Protocol 
Small Phantom Medium Phantom  Large Phantom 
Mean SD Ext Val Mean SD Ext Val Mean SD Ext Val 
I and II 
β.VUE-10  0.159 0.8689 0.564 -0.0065 0.8878 0.502 -2.3863 3.2323 0.238 
β.VUE-11 (12) 0.1644 0.8742 0.555 0.0605 0.8894 0.515 -2.2122 3.0847 0.25 
β.VUE-16 (22) 0.1768 0.9766 0.56 0.2176 0.9704 0.56 -2.525 3.427 0.226 
β.VUE-29 (36) 0.0786 0.8685 0.524 0.0977 0.8711 0.531 -1.8309 2.9779 0.273 
III 
β.VUE-10  -16.3479 0.9537 0 -13.8417 0.858 0 -7.5158 1.4429 0 
β.VUE-11 (12) -16.4564 0.9552 0 -14.2445 0.863 0 -6.9222 1.4306 0 
β.VUE-16 (22) -16.5018 0.9606 0 -14.0403 0.8465 0 -8.6903 1.3984 0 
β.VUE-29 (36) -16.2392 0.9296 0 -14.3276 0.8613 0 -7.4961 1.4352 0 
IV and V 
β.VUE-10 -8.1564 1.1752 0 -9.0207 1.5786 0 -9.7155 1.7239 0 
β.VUE-11 (12) -9.722 1.2145 0 -10.1018 1.6279 0 -7.9408 1.7143 0 
β.VUE-16 (22) -9.3679 1.2082 0 -9.4814 1.6648 0 -10.9021 1.765 0 
β.VUE-29 (36) -9.053 1.2733 0 -8.8473 1.6781 0 -8.372 1.6895 0 
Table 31. Summary of the results for differences in enhancement measurements when using 
VUE images (for each selected protocol) compared to TUE images as the baseline for 
calculation of enhancement (where the mean and SD values are for the difference in 
enhancement were computed in the Bayesian Hierarchical model, and are therefore not raw 
differences). The GSI protocol which varied least from TUE enhancement measurements 
for each scenario is highlighted. 
 
 87 
 
7. Bibliography 
1. J. T. Bushberg, J.A.S., E. M. Leidholdt Jr, J. M. Boone, The Essential Physics of Medical 
Imaging. 3rd ed. 2011, Philadelphia, Pa: Lippincott Williams and Wilkins. 
2. Kalender, W.A., X-ray computed tomography. Physics in medicine and biology, 2006. 
51(13): p. R29. 
3. Coursey, C.A., R.C. Nelson, D.T. Boll, E.K. Paulson, L.M. Ho, A.M. Neville, D. Marin, 
R.T. Gupta, and S.T. Schindera, Dual-energy multidetector CT: how does it work, what 
can it tell us, and when can we use it in abdominopelvic imaging? 1. Radiographics, 
2010. 30(4): p. 1037-1055. 
4. Brooks, R.A. and G. Di Chiro, Theory of Image Reconstruction in Computed 
Tomography 1. Radiology, 1975. 117(3): p. 561-572. 
5. Huda, W. and R.M. Slone, Review of radiologic physics. 2003: Lippincott Williams & 
Wilkins. 
6. Johnson, T.R., B. Krauss, M. Sedlmair, M. Grasruck, H. Bruder, D. Morhard, C. Fink, S. 
Weckbach, M. Lenhard, and B. Schmidt, Material differentiation by dual energy CT: 
initial experience. European radiology, 2007. 17(6): p. 1510-1517. 
7. Marin, D., D.T. Boll, A. Mileto, and R.C. Nelson, State of the Art: Dual-Energy CT of 
the Abdomen. Radiology, 2014. 271(2): p. 327-342. 
8. N. Chandra, D.A.L., T. R. C. Johnson, Gemstone Detector: Dual Energy Imaging via 
Fast kVp Switching, in Dual Energy CT in Clinical Practice. 2011, Medical Radiology. p. 
35-41. 
9. Graser, A., T.R. Johnson, E.M. Hecht, C.R. Becker, C. Leidecker, M. Staehler, C.G. 
Stief, H. Hildebrandt, M.C. Godoy, and M.E. Finn, Dual-energy ct in patients suspected 
of having renal masses: Can virtual nonenhanced images replace true nonenhanced 
images? 1. Radiology, 2009. 252(2): p. 433-440. 
 88 
 
10. Mendonça, P.R., R. Bhotika, M. Maddah, B. Thomsen, S. Dutta, P.E. Licato, and M.C. 
Joshi. Multi-material decomposition of spectral CT images. in SPIE Medical Imaging. 
2010. International Society for Optics and Photonics. 
11. Alvarez, R.E. and A. Macovski, Energy-selective reconstructions in x-ray computerised 
tomography. Physics in medicine and biology, 1976. 21(5): p. 733. 
12. Kalender, W.A., W. Perman, J. Vetter, and E. Klotz, Evaluation of a prototype dual‐
energy computed tomographic apparatus. I. Phantom studies. Medical physics, 1986. 
13(3): p. 334-339. 
13. Chandra, N., Material Attenuation Coefficient in GE presentation, D.E. Physics, Editor. 
14. Xu, D., D.A. Langan, X. Wu, J.D. Pack, T.M. Benson, J.E. Tkaczky, and A.M. Schmitz. 
Dual energy CT via fast kVp switching spectrum estimation. in SPIE Medical Imaging. 
2009. International Society for Optics and Photonics. 
15. Bosniak, M.A., Diagnosis and management of patients with complicated cystic lesions of 
the kidney. AJR. American journal of roentgenology, 1997. 169(3): p. 819-821. 
16. Bosniak, M.A., The current radiological approach to renal cysts. Radiology, 1986. 
158(1): p. 1-10. 
17. Israel, G.M. and M.A. Bosniak, How I Do It: Evaluating Renal Masses 1. Radiology, 
2005. 236(2): p. 441-450. 
18. Israel, G.M. and M.A. Bosniak, Pitfalls in Renal Mass Evaluation and How to Avoid 
Them 1. Radiographics, 2008. 28(5): p. 1325-1338. 
19. E. Cho, H.O.A., P. Lindblad, Epidemiology of Renal Cell Carcinoma. Hematology/ 
Oncology Clinics 25(4): p. 651-665. 
20. Institute, N.C., SEER Stat Fact Sheets: Kidney and Renal Pelvis Cancer, Surveillance 
Research Program: http://seer.cancer.gov/statfacts/html/kidrp.html. 
21. G. M. Israel, M.A.B., An Update of the Bosniak Renal Cyst Classification System. 
Urology, 2005. 66: p. 484-488. 
 89 
 
22. Pooler, B.D., P.J. Pickhardt, S.D. O’Connor, R.J. Bruce, S.R. Patel, and S.Y. Nakada, 
Renal cell carcinoma: attenuation values on unenhanced CT. American Journal of 
Roentgenology, 2012. 198(5): p. 1115-1120. 
23. Song, C., G.E. Min, K. Song, J.K. Kim, B. Hong, C.-S. Kim, and H. Ahn, Differential 
diagnosis of complex cystic renal mass using multiphase computerized tomography. The 
Journal of urology, 2009. 181(6): p. 2446-2450. 
24. Macari, M. and M.A. Bosniak, Delayed CT to Evaluate Renal Masses Incidentally 
Discovered at Contrast-enhanced CT: Demonstration of Vascularity with 
Deenhancement 1. Radiology, 1999. 213(3): p. 674-680. 
25. J. K. Kim, S.Y.P., J. H. Shon, K. S. Cho, Angiomyolipoma with Minimal Fat: 
Differentiation from Renal Cell Carcinoma at Biphasic Helical CT. Radiology, 2004. 
230: p. 677-684. 
26. C. W. Yang, S.H.S., Y. H. Chang, H. J. Chung, J. H. Wang, A. TL. Lin, K. K. Chen, Are 
there useful CT features to Differentiate Renal Cell Carcinoma from Lipid-Poor Renal 
Angiomyolipoma? AJR. American journal of roentgenology, 2013. 201(5): p. 1017-28. 
27. Maddah, M., P.R. Mendonça, and R. Bhotika. Physically meaningful virtual unenhanced 
image reconstruction from dual-energy CT. in Biomedical Imaging: From Nano to 
Macro, 2010 IEEE International Symposium on. 2010. IEEE. 
28. Song, K.D., C.K. Kim, B.K. Park, and B. Kim, Utility of iodine overlay technique and 
virtual unenhanced images for the characterization of renal masses by dual-energy CT. 
American Journal of Roentgenology, 2011. 197(6): p. W1076-W1082. 
29. Barrett, T., D. Bowden, N. Shaida, E. Godfrey, A. Taylor, D. Lomas, and A. Shaw, 
Virtual unenhanced second generation dual-source CT of the liver: is it time to discard 
the conventional unenhanced phase? European journal of radiology, 2012. 81(7): p. 
1438-1445. 
 90 
 
30. De Cecco, C.N., A. Darnell, N. Macías, J.R. Ayuso, S. Rodríguez, J. Rimola, M. Pagés, 
Á. García-Criado, M. Rengo, and A. Laghi, Virtual unenhanced images of the abdomen 
with second-generation dual-source dual-energy computed tomography: image quality 
and liver lesion detection. Investigative radiology, 2013. 48(1): p. 1-9. 
31. Moon, J., B. Park, C. Kim, and S. Park, Evaluation of virtual unenhanced CT obtained 
from dual-energy CT urography for detecting urinary stones. Evaluation, 2012. 85(1014). 
32. Takahashi, N., R.P. Hartman, T.J. Vrtiska, A. Kawashima, A.N. Primak, O.P. Dzyubak, 
J.N. Mandrekar, J.G. Fletcher, and C.H. McCollough, Dual-energy CT iodine-subtraction 
virtual unenhanced technique to detect urinary stones in an iodine-filled collecting 
system: a phantom study. AJR. American journal of roentgenology, 2008. 190(5): p. 
1169. 
33. Sommer, C.M., C.B. Schwarzwaelder, W. Stiller, S.T. Schindera, U. Stampfl, N. 
Bellemann, M. Holzschuh, J. Schmidt, J. Weitz, and L. Grenacher, Iodine removal in 
intravenous dual-energy CT-cholangiography: Is virtual non-enhanced imaging effective 
to replace true non-enhanced imaging? European journal of radiology, 2012. 81(4): p. 
692-699. 
34. Pache, G., B. Krauss, P. Strohm, U. Saueressig, P. Blanke, S. Bulla, O. Schäfer, P. 
Helwig, E. Kotter, and M. Langer, Dual-Energy CT Virtual Noncalcium Technique: 
Detecting Posttraumatic Bone Marrow Lesions—Feasibility Study 1. Radiology, 2010. 
256(2): p. 617-624. 
35. Reagan, A.C., P.I. Mallinson, T. O’Connell, P.D. McLaughlin, B. Krauss, P.L. Munk, S. 
Nicolaou, and H.A. Ouellette, Dual-Energy Computed Tomographic Virtual Noncalcium 
Algorithm for Detection of Bone Marrow Edema in Acute Fractures: Early Experiences. 
Journal of computer assisted tomography, 2014. 
36. Yamada, S., T. Ueguchi, T. Ogata, H. Mizuno, R. Ogihara, M. Koizumi, T. Shimazu, K. 
Murase, and K. Ogawa, Radiotherapy treatment planning with contrast-enhanced 
 91 
 
computed tomography: feasibility of dual-energy virtual unenhanced imaging for 
improved dose calculations. Radiation Oncology, 2014. 9(1): p. 1-10. 
37. Graser, A., C.R. Becker, M. Staehler, D.A. Clevert, M. Macari, N. Arndt, K. Nikolaou, 
W. Sommer, C. Stief, and M.F. Reiser, Single-phase dual-energy CT allows for 
characterization of renal masses as benign or malignant. Investigative radiology, 2010. 
45(7): p. 399-405. 
38. L. Wang, B.L., X. Wu, J. Wang. Y. Zhou, W. Wang, X. Zhu, Y. Yu. X. Li, S. Zhang, Y. 
Shen, Correlation between CT attenuation value and iodine concentration in vitro: 
Discrepancy between gemstone spectral imaging on single-source dual-energy CT and 
traditional polychromatic X-ray imaging. Journal of Medical Imaging and Radiation 
Oncology, 2012. 56: p. 379-383. 
39. A. Jonisch, A.N.R., P. G. Mutalik, G. M. Israel, Can High-Attenuation Renal Cysts be 
Differentiated from Renal Cell Carcinoma at Unehanced CT? Radiology, 2007. 243(2): 
p. 445-450. 
40. R. Vikram, C.S.N., P. Tamboli, N. M. Tannir, E. Jonasch, S. F. Matin, C. G. Wood, C. 
M. Sandler, Papillary Renal Cell Carcinoma: Radiologic-Pathologic Correlation and 
Spectrum of Disease. RadioGraphics, 2009. 29: p. 741-757. 
41. Taylor, J.R., An Introduction to Error Analysis: the study of uncertainties in physical 
measurements. Second Edition ed. 1982: Maple-Vail book manufacturing group. 
42. Viera, A.J. and J.M. Garrett, Understanding interobserver agreement: the kappa statistic. 
Fam Med, 2005. 37(5): p. 360-363. 
43. Toepker, M., T. Moritz, B. Krauss, M. Weber, G. Euller, T. Mang, F. Wolf, C.J. Herold, 
and H. Ringl, Virtual non-contrast in second-generation, dual-energy computed 
tomography: reliability of attenuation values. European journal of radiology, 2012. 
81(3): p. e398-e405. 
 92 
 
44. D. Zhang, X.L., B. Liu, Objective characterization of GE Discovery CT750 HD scanner: 
Gemstone spectral imaging mode. Med Phys, 2011. 38: p. 1178-1188. 
45. M. Goodsitt, E.G.C., S. C. Larson, Accuracies of the synthesized monochromatic CT 
numbers and effective atomic numbers obtained with a rapid kV switching dual energy 
CT scanner. Med Phys, 2011. 38(4): p. 2222-2232. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 93 
 
8. Vita 
 
 Dawn Olivia Popnoe was born in New Port Richey, Florida on May 10, 1991, the 
daughter of Mark Thomas Skeen and Victoria Marie Skeen. After graduating Valedictorian of 
Okeechobee High School, Okeechobee, Florida in 2009 she entered Angelo State University in 
San Angelo, Texas. She received Bachelor of Science degrees with a major in Physics and a 
major in Mathematics. In August of 2013 she entered the Medical Physics Master’s program at 
The University of Texas Graduate School of Biomedical Sciences at Houston. After graduation, 
Olivia plans to continue her education by pursing a Doctorate of Medical Physics at the 
University of Texas Health and Science Center in San Antonio, Texas.  
 
Permanent Address: 
608 N 23rd St 
Lamesa, Tx 79331 
